
==== Front
Curr Neuropharmacol
Curr Neuropharmacol
CN
Current Neuropharmacology
1570-159X
1875-6190
Bentham Science Publishers

37622689
CN-22-1778
10.2174/1570159X21666230824091601
Medicine, Neurology, Pharmacology, Neuroscience
Pathomechanistic Networks of Motor System Injury in Amyotrophic Lateral Sclerosis
Dey Bedaballi 12
Kumar Arvind 12
Patel Anant Bahadur 12*
1 CSIR-Centre for Cellular and Molecular Biology (CSIR-CCMB), Hyderabad 500007, Telangana, India;
2 AcSIR-Academy of Scientific and Innovative Research, Ghaziabad 201002, Uttar Pradesh, India
* Address correspondence to this author at the Department of NMR, Microimaging and Spectroscopy, CSIR-Centre for Cellular and Molecular Biology (CSIR-CCMB), Hyderabad 500007, Telangana, India; E-mail: abpatel@ccmb.res.in
24 8 2023
2024
22 11 17781806
21 4 2023
25 5 2023
06 6 2023
© 2024 The Author(s). Published by Bentham Science Publishers
2024
The Author(s)
https://creativecommons.org/licenses/by/4.0/ © 2024 The Author(s). Published by Bentham Science Publishers. This is an open access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode.
Amyotrophic Lateral Sclerosis (ALS) is the most common, adult-onset, progressive motor neurodegenerative disorder that results in death within 3 years of the clinical diagnosis. Due to the clinicopathological heterogeneity, any reliable biomarkers for diagnosis or prognosis of ALS have not been identified till date. Moreover, the only three clinically approved treatments are not uniformly effective in slowing the disease progression. Over the last 15 years, there has been a rapid advancement in research on the complex pathomechanistic landscape of ALS that has opened up new avenues for successful clinical translation of targeted therapeutics. Multiple studies suggest that the age-dependent interaction of risk-associated genes with environmental factors and endogenous modifiers is critical to the multi-step process of ALS pathogenesis. In this review, we provide an updated discussion on the dysregulated cross-talk between intracellular homeostasis processes, the unique molecular networks across selectively vulnerable cell types, and the multisystemic nature of ALS pathomechanisms. Importantly, this work highlights the alteration in epigenetic and epitranscriptomic landscape due to gene-environment interactions, which have been largely overlooked in the context of ALS pathology. Finally, we suggest that precision medicine research in ALS will be largely benefitted from the stratification of patient groups based on the clinical phenotype, onset and progression, genome, exposome, and metabolic identities.

Keywords

Amyotrophic lateral sclerosis (ALS)
motor neuron disease
pathophysiology
gene environment interaction
heterogeneity
metabolism
epigenetics
RNA modification
==== Body
pmc1 INTRODUCTION

Amyotrophic Lateral Sclerosis (ALS) is the third most common type of neurodegenerative disorder and the most common type of ‘Motor Neurone Disease’ (MND) [1]. The global incidence of ALS currently ranges between 0.6 and 3.8 per 100,000 person-years, which is increasing over time [2]. The prevalence of ALS is approximately 4.1-8.4 per 100,00 persons, with a lifetime risk of 1 in 350 and a median onset age of 51-66 years [3]. ALS initiates focally and asymmetrically in the upper and/or lower limbs or in the bulbar regions, followed by a gradual progression to the contiguous voluntary muscles [4]. Moreover, about 28% of sporadic and 48% of familial cases of ALS display cognitive deficits associated with frontotemporal dementia (FTD) [5]. Clinical hallmarks of ‘classical’ ALS cases involve progressive and concomitant degeneration of upper (UMN) and lower motor neurons (LMN) in the motor cortex, brain stem, and spinal cord [4]. Early clinical signs of UMN and/or LMN defects are followed by a progressive paralysis that causes death by respiratory failure in ≥ 50% of patients within 2-5 years of diagnosis [6]. Major sub-clinical signatures in ALS involve atrophy of the primary motor cortex and ventral projections of the spinal cord, degeneration of the corticospinal and corticobulbar tracts, degeneration of the hypoglossal-trigeminal-phrenic nerves of the brain stem, and wasting of the somatic and bulbar skeletal muscles [7]. Underlying microstructural abnormalities include massive death of spinal α-motor neurons and varying loss of corticomotor Betz cells, with diffuse gliosis in the subcortical white matter and the grey matter of the motor cortex and spinal cord [7].

Gender-based risk of ALS incidence is approximately double for the male sex [8], with a higher mean age at diagnosis and a lower peak age of prevalence among women [9]. Interestingly, a lower survival time with a higher risk of bulbar onset has been reported in women [10]. However, these gender ratios might change with the age of incidence, both geographically and temporally [11]. A higher incidence in Europe compared to South and East Asia has been correlated with the lower prevalence of known ALS genes in Asian populations [3, 11]. The presence of a prodromal delay, respiratory or genitourinary comorbidities, gradual weight loss or poor nutritional status, and cognitive impairment or depressive disorders tend to negatively affect survival in ALS patients [3]. Based upon their representativeness across various population-based studies, the above factors can act as the demographic variants that skew the association of disease with prognostic factors.

Due to a wide variety of ‘ALS-mimic’ disorders, the use of a range of diagnostic methods involving clinical, electrophysiological, neuroimaging, and neuropathological tests is required to ascertain the ALS ‘syndrome’ [12]. A definitive diagnosis of ALS requires the revised El Escorial criteria with the revised Airlie House criteria from the World Federation of Neurology (WFN), the Awaji-Shima criteria, and the Gold Coast criteria [13-15].

As revealed by various large-scale epidemiological studies, a wide range of susceptibility factors and resistance mechanisms contribute to the variability of disease progression and survivability in ALS [4]. The complex etiology of the ALS spectrum is believed to be the result of a time-variable cross-talk between environmental risk factors and endogenous metabolic modifiers, with diverse types of genetic polymorphisms having different cytotoxic or cytoprotective effects depending on neuronal types [16].

In this review, we highlight the complex interplay of impaired cellular processes that define the pathomechanistic signature during ALS onset and progression. This majorly involves synaptic failure, neuroinflammation, dysregulated proteostasis and RNA metabolism, impaired endosomal trafficking and axonal transport, oxidative stress, DNA damage, and metabolic dyshomeostasis [17]. The complex genetic architecture of ALS dictates the molecular heterogeneity of affected cellular networks and generates a ‘pathological continuum’ of clinical phenotypes. Moreover, this review draws a focus on the multisystem nature of pathological processes, the selective vulnerability of motor neuron and myofibre subtypes, and the dysregulated neuroglial and neuromuscular networks in ALS ‘syndrome’ [18].

Additionally, hurdles in unraveling the ‘missing heritability’ of ALS pathogenesis can be overcome by looking in the direction of DNA or RNA modifications associated with the disease. Here, we describe the critical role of gene-environment interaction in disease precipitation in conjunction with the dysregulated epigenetic machinery and epitranscriptomic landscape in ALS. Finally, we suggest that the need of the hour is to discern how the pathological cellular networks work simultaneously, sequentially, or synergistically in ALS.

2 GENETIC RISK FACTORS OF ALS

Traditionally, over 90-95% of cases of ALS are determined to be sporadic (sALS), and only 5-10% of cases have a familial origin (fALS), usually with an autosomal dominant inheritance pattern [19]. Over the years, >50 potentially causative or disease-modifying genes associated with ALS have been identified [20]. The genetic component in 60-70% of fALS cases is known, while the heritability of sALS cases lies at 50% [21]. Approximately 50% of fALS cases and 5% of sALS cases are attributed to high-risk genes such as chromosome 9 open reading frame 72 (C9ORF72), superoxide dismutase (SOD1), TAR-DNA binding protein (TARDBP) and fused in sarcoma (FUS) [20].

A multitude of genes associated with ALS reveals shared contribution to endocytosis and vesicle transport such as alsin 2 (ALS2), vesicle membrane protein-associated protein B (VAPB), optineurin (OPTN), and valosin-containing protein (VCP), along with axonal transport and organelle traffickings such as spatacsin (SPG11) and OPTN [20, 22]. Other genes are involved in autophagy such as TANK-binding kinase 1 (TBK1), charged multivesicular body protein 2B (CHMP2B), Sequestosome 1 (SQSTM1) and OPTN, or protein degradation and unfolded protein response such as ubiquilin 2 (UBQLN2) and sigma non-opioid intracellular receptor 1 (SIGMAR1), or oxidative stress response such as SOD1, or DNA damage and RNA metabolism such as angiogenin (ANG), senataxin (SETX), heterogenous nuclear ribonucleoprotein A1/A2 (HNRNPA1/A2), C9ORF72, TARDBP, and FUS [7, 20].

Many of the fALS-associated mutations have now been reported in sALS cases, being previously undetected due to incomplete genotypic penetrance, delayed disease onset, and/or oligogenic contribution [23]. Analyses of various large-scale genome-wide association studies contribute to the ‘multiple rare variants, common disease’ hypothesis of sporadic ALS [24]. Moreover, the genetic contribution to the risk of ALS onset and the rate of progression seems to be independent of each other [25]. It is yet unclear how the mutations in individual ALS-associated genes having divergent cellular functions ultimately converge on the signature disease phenotype. It has become apparent that systematic genetic profiling of both familial and sporadic ALS patients followed by a genetic sub-classification is crucial for the development of targeted therapeutics and relevant preclinical models for drug screening.

3 PATHOPHYSIOLOGY OF ALS

Contiguity of the degenerative spreading through the central nervous system (CNS) is indicated by the decline in the integrity of multiple interconnected micro-circuits within and associated with the motor network [26]. These circuits involve ‘determinants’ such as the quadripartite network of neuron-oligodendrocyte-astrocyte-microglia cell types, the neuromuscular synapse, the inhibitory feedback connections with interneurons, as well as ‘contributors’ across the neurovascular units such as lymphocytes and pericytes [26]. Here, we discuss the currently available knowledge of the pathophysiological mechanisms of ALS.

3.1 Multifaceted Pathology of Synaptic Failure

ALS is often regarded as a synaptopathy, wherein motor degeneration is preceded by a loss of synaptic scaling and plasticity [26, 27]. This occurs with concomitant regression and degeneration of synaptic architecture and apical dendrites [27, 28].

3.1.1 Effects on Motor Neurons

Accumulation of mutant protein aggregates in astroglia (e.g., SOD1, FUS) has been found to hyperactivate nuclear factor kappa B (NF-κB) and tumor necrosis factor α (TNF-α) signaling, which disrupts synaptic scaling [29]. It works through the astrocyte-mediated upregulation of the Ca2+ permeable types of the α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) glutamate receptors like GluR1, with a concomitant increase in the intrinsically Ca2+ -permeable N-methyl-D-aspartic acid (NMDA) glutamate receptor subunits like GluN3B in postsynaptic neurons [30]. Upregulation of metabotropic glutamate receptors like mGlu1 or mGlu5 in presynaptic neurons or astroglia, respectively; along with activation of astroglial serotonergic receptor 5-HT2B, overstimulates the glutamate release machinery [31, 32]. Inhibition of neuron-stimulated astroglial transcriptional activator κB-motif binding phosphoprotein (KBBP), and astroglial accumulation of reactive oxygen species (ROS) downregulates the astroglial glutamate reuptake transporter GLT1 [33]. At a symptomatic stage in sALS patients and transgenic SOD1G93A mice, ‘synaptic stripping’ of the cholinergic connections from lower motor neurons (LMNs) to the inhibitory interneurons is concomitant with the loss of the feedback glycinergic and γ-aminobutyric acid (GABAergic) synapses from the inhibitory Renshaw cells to LMNs [34].

Altogether, the gain of excitatory drive and loss of inhibitory regulation increases Ca2+ influx and triggers a sustained neuronal depolarization [35]. Due to the lack of Ca2+ -buffering proteins, defects in the Ca2+ ATPase pump and Ca2+/Na+ exchangers, and upregulation of voltage-gated Ca2+ channels, the neuronal hyperexcitability disrupts the intracellular Ca2+ homeostasis cycle across the endoplasmic reticulum (ER) and mitochondria [36, 37]. This leads to cellular ATP depletion and increased ROS production, which in turn triggers Na+/K+ ATPase pump dysfunction and further enhances neuronal firing [28]. Thus, the local motor circuitry is compromised to glutamate excitotoxicity. Notably, there are differences in opinion regarding the region of origin and the course of disease progression in ALS, influenced by the variable vulnerability of motor neurons and muscle fibre types (Fig. 1).

3.1.2 Effects on Neuromuscular Junctions

Mutant protein aggregates of SOD1 in skeletal muscles sequester cytoskeletal proteins like kinesin-associated protein (KAP3) [38]. Along with the downregulation of the acetylcholine transporter ChAT, this process inhibits acetylcholine (ACh) release from LMNs [38]. Overall, it results in the dismantling of neuromuscular junctions (NMJ) and a loss of myofibre contractility [39].

Release of neuronal growth-cone repellents like Nogo-A from skeletal muscles and chemorepellents like semaphorin-3A (SEMA3A) from dysfunctional terminal Schwann cells (TSCs) have been found to alter synaptic cytoskeletal dynamics by reducing phosphoglycerate kinase 1 (PGK1) production and by neuropilin (NRP) signaling, respectively [40, 41]. Concomitantly, various non-guidance factors from terminal Schwann cells and damaged myofibres alter the cell-cell adhesion networks [42, 43]. Along with an upregulation of denervation inducers or reinnervation inhibitors such as muscle-specific acetylcholine receptor subunits (AChRα1) or neuronal tyrosine kinases (ephrin type-A receptor 4, i.e., EPHA4), these processes trigger distal axonopathy [44, 45]. Activation of aberrant acetylcholine receptors due to denervation (γ-AChR) and maladaptive reinnervation (ε-AChR) at the motor end plate disrupts the firing rate, connectivity, and regeneration potential of neurons [46]. This, in turn, enhances the fatigability of myofibres during spontaneous muscarinic activation [47]. Notably, axonal retraction at NMJs precedes neuronal death in SOD1G93A mice and is in turn, preceded by a loss of TSCs [48, 49]. At the early stages of ALS, exhaustive rounds of regeneration and aberrant electrochemical activation deplete myogenic satellite cells [50].

3.1.3 Selective Vulnerability of Motor Neuron and Skeletal Myofibre Subtypes

ALS-vulnerable fast-firing fast-fatigable (FF) motor neurons have larger cell bodies, faster axonal conduction velocity, elaborate dendritic branching, and high NMJ innervation as compared to the ALS-resistant slow-twitch fatigue-resistant (S-type) motor neurons [51]. FF motor neurons (MNs) innervate the fast-contracting extrafusal myofibres, while S-type neurons connect with the slow intrafusal fibres [37]. Moreover, ALS-vulnerable MNs are susceptible to oxidative stress and proteostasis dysregulation due to the low levels of free-radical scavengers and cytosolic calcium buffering proteins (e.g., parvalbumin, calbindin, calreticulin) [52].

Overactivation of osteopontin-integrin-matrix metalloprotein 9 axis is involved in ER-stress-induced inflammation in FF neurons, with a concomitant upregulation of neurofilament proteins of retrograde transport. Moreover, upregulation of SIL1, the co-chaperone of ER-resident binding immunoglobulin protein (BiP), induces unfolded protein response (UPR); while the insulin growth factor (IGF-2/IGF-1) signalling protects against glutamate excitotoxicity in S-type neurons [37]. FF neurons express the Na+/K+ ATPase-α3 subunit that is selectively impaired by mutant proteins, while S-type neurons express the resilient Na+/K+ ATPase-α1 subunit [53]. Neuronal vulnerability is also dictated by the differential expression of GABAA-α2 and GLUR1 on FF neurons, with GABAA-α1 and GLUR2 on S-type neurons [54]. Notably, the apoptosis-inducing factor SEMA3A is secreted by the ALS-vulnerable type-IIb fast-twitch glycolytic myofibres, while the ALS-resistant type-I slow-twitch oxidative myofibres secrete SEMA3E [51]. Intriguingly, presynaptic Na+ channels (ENaC) can slow down the synaptic dysfunction by inducing a non-selective ‘presynaptic homeostatic plasticity’ at ALS-affected NMJs [55].

Although the dysfunction of motor circuitry is profound in ALS, there is evidence of sensory neuronal abnormalities across the heterogenous population of ALS patients. This enforces the idea of the multisystem nature of disease progression in ALS (details in Box 1).

At presymptomatic stage, the synaptic dysfunction of fast fatigable α-MNs reduces the activity of fast contractile myofibres, and induces an increase in glutamatergic spindle-afferent inputs to α-MNs. This process triggers the excitotoxic death [60]. Hence, it is not clear whether hyperexcitability triggers neurodegeneration, or it arises to compensate neuronal death [61].

It is important to note that the differences in vulnerability of specific motor neuron or muscle fibre types potentially regulate the dominant heterogeneity in UMN and LMN involvement across various ALS phenotypes depending on the site of onset. A new line of ALS research is currently focused on targeting the unique structural, functional, and molecular features of these cell types for developing targeted preventive or therapeutic measures.

3.2 Non-cell Autonomous Neuroinflammation

Reactive microgliosis progresses in motor and even extra motor areas since the early presymptomatic stage [62]. It is preceded by reactive astrocytosis with regionally variable activation through inherent defects or paracrine signalling from neurons [63]. Given the dual role of astroglia in neuroprotection and neurotoxicity, a chronic disease state can drive an adaptive CNS-specific response towards systemic hyper-inflammation [64].

3.2.1 Innate Immune Response

In the spinal cord of ALS patients and transgenic mouse models, cell-specific accumulation of mutant protein aggregates (SOD1, TDP43) induces the secretion of chemokines such as monocyte attractant MCP1 and B-cell attractant CXCL13 [65]. It also triggers the production of oxidative stress mediators such as ROS, inducible nitric oxide synthase (iNOS), cyclooxygenase 2 (COX2), and prostaglandin E2 (PE2) [66]. This, in turn, drives the production of pro-inflammatory cytokines such as TNF-α, interferon γ (IFN-γ), and interleukin 1β (IL-1β) [63]. Furthermore, it reduces the secretion of neurotrophic factors such as IGF-2, glial cell-derived neurotrophic factor (GDNF), brain-derived neurotrophic factor (BDNF), and vascular endothelial growth factor (VEGF) from microglia and astrocytes [67].

Microglia can be directly activated by chemokines or indirectly by mutant protein aggregates, excitotoxic stimuli, and extracellular ATP [68]. At a presymptomatic stage, the toxicity of mutant proteins in astrocytes induces Wnt/β-catenin signaling-dependent anti-inflammatory M2 microglial activation [69]. However, chronic NF-κB activation triggers reactive gliosis with inflammasome formation and blood-CNS barrier disruption [69]. Consequently, the pro-inflammatory M1 microglia secrete factors (TNF-α, IL-1α, C1q) to induce the neurotoxic A1 phenotype in astrocytes [70]. Together with the exosomal transport of astrocytic regulatory microRNAs and misfolded protein aggregates, the overexpression of astrocytic gap junction proteins (e.g., connexin-43) facilitates the rapid spread of glial toxicity to the neighbouring cell types [71].

Despite the glial overexpression of the anti-inflammatory toll-like receptor (TLR2) at the presymptomatic stage, the activity of the pro-inflammatory receptor TLR4 in neurons induces a net neurotoxic environment [72]. At later stages, upregulation of high mobility group protein 1 (HMGB1), the inflammasome marker, exacerbates proinflammatory pathways through astroglial TLR4 signalling and microglial RAGE signalling [73, 74]. Altogether, these constitute the self-perpetuating cycle of microglial overactivation and neurodegeneration [62]. Additionally, astroglia mediates the infiltration of neutrophils and peripheral macrophages or monocytes through the secretion of specific chemoattractants such as MCP1, CXCL8, galectin-1, osteopontin, and macrophage colony-stimulating factor (M-CSF) [63]. Notably, variations in the 3’-untranslated region (3’-UTR) of the gene encoding interleukin-18 receptor accessory protein (IL18RAP) can regulate NF-κB signalling to prevent neurotoxicity of induced pluripotent stem cell (iPSC)-derived microglia from C9orf72 ALS patients [75].

3.2.2 Adaptive Immune Response

At early stages, infiltration of CD4+ helper T-cells (Th) maintains a net neuroprotective niche through the secretion of anti-inflammatory cytokines (IL-4, transforming growth factor β, i.e., TGF-β), and the stimulation of astrocytic GLT1 activity [76]. Downregulation of regulatory T-cells (Treg) and Th2 cells through the forkhead box P3 (FOXP3) and GATA-binding protein 3 (GATA3) transcription factors accelerates disease progression [77]. Moreover, Th17 and Th1 cells secrete proinflammatory cytokines (IL-17, IL-23, IL-10, IFN-γ) upon infiltration into the CNS microenvironment [78]. Together, these processes also upregulate the pro-inflammatory purinergic receptors P2X7 and P2Y12 in astroglia to induce inflammasome formation and caspase-1 activation [73, 79]. Activated CD14+ microglial cells acquire the characteristic surface markers of dendritic cells (CD11c, CD86, CD54), which promotes an adaptive immune response [63]. At later stages, cytotoxic CD8+ T-cells and natural killer cells infiltrate the CNS microenvironment through microglial pro-inflammatory TLR response and MN-specific antigen presentation [67, 78]. Additionally, diseased neurons secrete subunits of the complement system (e.g., C1q, C3, C4, C5b-9) to relay the stress signalling to neighbouring cells [80]. Although the role of B-lymphocytes in ALS pathology is unclear, autoantibodies observed at end stages (e.g., those against HMGB1, P/Q-type voltage-gated Ca2+ channel, AChR) indicate aberrant autoimmune activation [67].

3.2.3 Role of Blood-CNS Barrier in Neuroinflammation

In medulla oblongata and spinal cord from sALS patients and transgenic SOD1 mice, the presence of dysfunctional microvessels indicates pervasive damage to the blood-brain barrier (BBB) and blood-spinal cord barrier (BSCB) with micro-haemorrhages [81]. This phenomenon hampers the recruitment of anti-inflammatory macrophages and Treg cells and induces a toxic neurovascular inflammatory response [81]. Ultrastructural analysis of the choroid plexus in ALS patients revealed the loss of tight junction components, disruption of vascular integrity, vascular injury, and loss of pericytes [82].

Currently, the initiation of immune response and the nature of the involvement of specific immune cells in ALS onset and progression have not been completely understood. This is because of the chronic nature and late diagnosis of ALS, which makes it difficult to determine whether abnormal immune response or inflammation is a cause or consequence of the disease [83].

3.3 Disrupted Neuron-astroglial Interactions

3.3.1 Role in Pathogenic Processes

Disrupted intracellular Ca2+ signalling in astrocytes triggers the release of excitotoxic gliotransmitters (glutamate, D-serine) and proinflammatory factors that impair glutamate reuptake [71]. Additionally, astrocytic GLT1 expression is downregulated by NF-κB signalling through membralin depletion and metadherin upregulation [84, 85]. Upon cleavage by caspase-3 and the addition of small ubiquitin-like modifier (SUMO), accumulation of the GLT1 C-terminal fragment induces the reactive astrocytic phenotype [86]. Moreover, abnormal upregulation of GABA or glycine transporters (GAT1 or GlyT2) in gliosomes, with concomitant dysregulation of astrocytic cystine/glutamate antiporter (xCT) stimulates glutamate release from astrocytes and decreases the antioxidant glutathione levels [71]. Microglia-neuron interaction is also disrupted by the dysregulation of CD200/CD200R immune receptor signalling at the presymptomatic stage and CX3CL1/CX3CR1 chemokine receptor signalling at the symptomatic stage, respectively [87, 88]. Intriguingly, downregulation of the antigen presentation element MHC-1 by astrocytes triggers ER stress in neurons through proteasomal dysfunction, whereas enhanced TGF-β1 secretion by astrocytes dysregulates neuronal autophagy [89].

3.3.2 Role in Loss of Neuroprotection

In ALS, there is a disruption of the metabolic coupling of spinal neurons with the astrocytes and oligodendrocytes. This results from the decreased transport of glycolytic products (lactate) for neuronal oxidative phosphorylation due to the loss of the astrocytic (MCT4) and oligodendrocytic (MCT1) lactate efflux transporters [90]. Together with the pro-nerve growth factor (pro-NGF) and p75 neurotrophin receptor (p75NTR) signalling in astrocytes during mitochondrial dysfunction, the neuroglial metabolic uncoupling triggers microglial activation [90]. There is a reduced secretion of astrocytic trophic factors that mediate neuroprotective cross-talk between astroglia and neurons such as BDNF, VEGF, NGF, plasminogen, basic fibroblast growth factor (bFGF), and neurotrophin 3/4 (NT-3/4) [91]. Death of oligodendrocytes reduces the secretion of trophic factors such as GDNF and ciliary neurotrophic factor (CNTF) to promote neurodegeneration [92] Interestingly, OPTN is known to inhibit NF-κB mediated astroglial activation, glutamate excitotoxicity, chronic inflammation, and necroptosis. Targeted depletion of OPTN in oligodendrocytes and microglia leads to reactive gliosis with demyelination and axonopathy [93]. Notably, microglial activation is facilitated by the necroptotic death of neurons and oligodendrocytes at early stages (details in Box 2).

3.3.3 Pathogenicity of Extracellular Biofluids

Chronic intracerebroventricular (i.c.v.) infusion of cerebrospinal fluid (CSF) from sALS patients into the transgenic mice expressing human TDP43 wild-type protein (hTDP43WT) induces cytoplasmic phosphorylated TDP43 aggregates, alteration of electrophysiological properties of corticomotor neurons, with subsequent motor impairment in mice [99]. Similar in vitro experiments trigger aberrant phosphorylation and aggregation of neurofilaments, reduced expression of ChAT and Na+/K+ ion pumps, reactive gliosis, and necroptosis of neurons [100]. Mass spectrometric analysis of CSF from sALS patients revealed an upregulation of inflammatory proteins (chitotriosidase, osteopontin, chitinase-3-like protein 1) and pro-inflammatory cytokines (TNF-α, IL-6), along with downregulation of anti-inflammatory cytokines (IL-10, IFN-γ) [101]. Additionally, there was a decrease in the levels of trophic factors (VEGF, GDNF) and an increase in neurotoxic mediators (PE2, COX2, ROS, NO, glutamate) [101].

Deletion of mutant SOD1 allele from motor neurons and oligodendrocytes in a transgenic mouse model of ALS delays disease onset but not progression [102, 103]. Mutant SOD1 depletion from microglia slows down disease progression by 50% but not the onset [104]. Targeted overexpression of mutant SOD1 in astrocytes and oligodendrocytes does not trigger the ALS phenotype. This highlights the need for distinct therapeutic interventions targeting the non-cell autonomous pathology at definite stages of the disease [105].

3.4 Dysregulation of Autophagy

Motor neurons (MNs) are terminally differentiated cells that heavily depend on constitutive autophagy for the clearance of misfolded protein aggregates, accumulated stress granules, damaged organelles, and defective cargo-loaded presynaptic vesicles [106]. Interestingly, autophagy displays a dual mode of action in ALS pathology. Activation of autophagy protects MNs and NMJs from an accumulation of mutant protein aggregates at the presymptomatic stage, whereas it mediates disease progression at the symptomatic stage. In spinal neurons and senescent skeletal muscles of ALS patients and mouse models, the accumulation of autophagosomes in the inclusion bodies at the symptomatic stage indicates an impairment of autophagy [107, 108]. Furthermore, transcription-independent accumulation of early-step autophagy factors (e.g., Beclin-1, p62/SQSTM1, LC3-II, Atg5-Atg12 complex) is observed in motor neurons at the presymptomatic stage and in astroglia at later stages [109].

Over-induction of autophagy occurs as an adaptive response to a concomitant milieu of cellular stressors such as DNA damage stress, proteotoxic stress, ER stress, and oxidative stress. Increased autophagosome formation exceeds the lysosomal degradation rate and subsequently triggers apoptosis and type II cell death (autophagic-lysosomal) in various neurodegenerative disorders [110]. This process is associated with the downregulation of BDNF and its receptor tropomyosin receptor kinase B (TrkB) signalling, which otherwise protects neurons through the phosphatidylinositol-3-kinase/ protein kinase B/mammalian target of rapamycin (PI3K/ PKB/mTOR) pathway [111]. Age-associated impairment of lysosomal activity occurs due to the intra-lysosomal aggregates of lipofuscin granules, various extra-lysosomal aggregates, and damaged mitochondria. Altogether, these processes inhibit autophagy, which potentially contributes to the late symptoms [109].

3.4.1 Autophagic Factors in ALS

The autophagic-lysosomal pathway can be disrupted by ALS-linked mutants of the core components or the modifier factors that regulate autophagic induction (C9ORF72, TBK1), autophagosome formation and maturation (OPTN, SQSTM1, TBK1, UBQLN2, VCP, VAPB), and autolysosome formation (C9ORF72, VCP, CHMP2B, ALS2) [109]. Loss-of-function C9orf72 mutations disrupt the transcription factor EB (TFEB) signalling of autophagic induction, impair the interaction with autophagy GTPases, and inhibit autolysosome formation [112, 113]. Repeat expansions from the gain-of-function C9orf72 mutations compromise the function of autophagy receptors like p62 and RNA-binding proteins like TDP43 by sequestering them in stress granules [114]. ALS-linked mutants of UBQLN2, p62, and OPTN impair the autophagic recognition of ubiquitinated aggresomes and damaged mitochondria [115]. TBK1 mutants impair the phosphorylation of autophagy receptors (p62, OPTN) and microtubule-binding proteins for cargo recognition and autolysosome formation [116].

Mutant SOD1 aggregates are known to inhibit mitophagy by sequestering OPTN, impair phagophore formation or expansion by binding the Beclin1-Bcl2 complex, and hinder autolysosome formation by sequestering the cytoskeletal dynein protein [109, 117]. Mutant TDP43 separately dysregulates mTOR-independent and mTOR-dependent autophagy by inhibiting the nuclear translocation of autophagy transcription factors (FOXO, TFEB), and by destabilizing the transcripts of autophagy factors (ATG7, DYNACTIN1, RAPTOR) [113, 118]. Mutant FUS dysregulates autophagy through the accumulation of autophagy receptors p62 and neighbour of BRCA1 gene 1 (NBR1) [119]. Furthermore, mutant HNRNPA1 is known to disrupt Beclin1 activity and stress granule dynamics to impair autophagic flux [120].

Notably, the autophagic machinery cross-talks with multiple cellular processes in order to regulate ALS pathogenesis. UBQLN2 can mediate the autophagy-independent degradation of aggresomes by proteasomal machinery, while it can exacerbate NF-κB mediated inflammatory response [121]. Furthermore, OPTN and p62 can regulate inflammatory response and necroptosis by interacting with TBK1 [116].

3.5 Blocked Axonal Transport

As polarized and elongated cells, motor neurons are susceptible to defects in endosomal trafficking and axonal transport due to the demand of a high turnover of membrane components, cargo-loaded vesicles, and mitochondria required for synaptic activity [122].

3.5.1 Cytoskeletal Proteins in ALS

At early stages, mutant SOD1 impairs the anterograde transport in a cargo-specific manner, whereby dysfunctional mitochondria dissociate from the molecular motors of axonal transport [123]. Sequestration of the cytoskeletal dynein protein in stress granules (SG) by mutant SOD1 inhibits retrograde axonal transport and impairs the clearance of aggregates in neurons [124]. Loss-of-function C9ORF72 mutants disrupt the actin-mediated transport of lysosomal proteins and their association with early endosomes [125]. Loss-of-function OPTN mutants disrupt its interaction with myosin VI and impair the retrograde transport for autolysosome formation [126]. ALS-linked mutants of the tubulin-associated protein TUBA4A perturb the dynamics and stability of microtubules [127]. Mutants of profilin 1 (PFN1) disrupt its association with actin, while those in dynactin (DCTN) impair the formation of the microtubule-binding complex [109]. ALS-linked mutants of the p150Glued subunit of the dynein/dynactin complex also affect the binding to microtubules [128]. Notably, mutants of DCTN, PFN1, and TUBA4A are also known to dysregulate autophagy [109]. While the mutant forms of SOD1 and FUS can affect kinesins by altering their expression or phosphorylation state, the ALS-associated pathologic mutants of kinesin-5A have also been reported [109, 129].

3.5.2 Neurofilaments in ALS

Upregulation of TNF-α perturbs the kinesin activity through p38 mitogen-activated protein kinase (MAPK) signalling, and impairs the anterograde transport [130]. Elevated glutamate levels impede the axonal transport of neurofilament heavy chain (NF-H) through phosphorylation [131]. Importantly, the accumulation of neurofilament light and medium chain proteins (NF-L, NF-M) along the axon acts as a pathological hallmark of ALS [109]. This is concomitant with the disruption of the neurofilament network and its reduced association with actin filaments and microtubules. Axonal transport defects at the presymptomatic stage impair synaptic transmission and exacerbate distal axonopathy [42].

3.6 Disruption of Endosomal Trafficking

Upon the disruption of the endosomal trafficking network, which cross-talks with autophagy and axonal transport, the viability of motor neurons (MNs) is critically impaired [122]. Cytoplasmic accumulation of mutant TDP43 disrupts the receptor signalling of cytokines to induce their mis-sorting towards early or recycling endosomes, which affects synaptic growth [132]. In iPSC-derived MNs from ALS patients carrying loss-of-function C9orf72 mutations, an increase has been observed in the transport of NMDA receptors and Ca2+ -permeable AMPA receptors to the surface of dendritic spines and neurites [125]. Moreover, defective transport of mannose-6-phosphate (M6P) receptors impairs the anterograde trafficking of lysosomal enzymes and cargo [125]. Due to the downregulation of vacuolar protein sorting VPS26, the endosomal retromer component, aberrant endosomal recycling has been reported for the BDNF/TrkB receptor [133]. These defects can arise from the disrupted interaction of C9ORF72 with Rab GTPases involved in the intracellular vesicle trafficking pathways [134].

Similar to C9ORF72, alsin (ALS2) protein is a guanine nucleotide exchange factor (GEF) for the GTPase RAB5. Loss of ALS2 impairs endosomal mobility, increases the conversion of endosomes to lysosomes, and enhances the degradation of synaptic cargo like glutamate receptors [135]. Furthermore, dysregulated endosomal trafficking can be triggered by various rare mutants of VAPB, OPTN, CHMP2B, and the multivesicular body biogenesis factor ESCRTIII [7]. Mutants of VCP impair endocytosis through disruption of the clathrin-associated complex, impair disassembly and autophagic degradation of SGs, and can also trigger TDP43 mislocalization [136, 137]. Along with autophagic dysregulation, FIG4 variants with impaired phosphatase activity can perturb the cellular abundance of phosphatidylinositol 3,5-bisphosphate, a signalling lipid involved in the retrograde transport of endosomal vesicles [138]. Intriguingly, the defects in nucleo-cytoplasmic transport in ALS involve aberrant sequestration of its components in SGs, with dysfunctional RAN GTPase activity [139]. FUS mutants disrupt the transportin-mediated nuclear import, whereas the nuclear egress of TDP43 and FUS mutants occurs independently of exportin-1 [140]. Fig. (2) provides an overview of the dysregulated intracellular pathogenic processes across the neuron-glia network affected in ALS.

3.7 Dysregulation of RNA Metabolism and Protein Homeostasis Machinery

Motor neurons (MNs) and skeletal muscles are known to bear a metastable sub-proteome, which is characterized by the super-saturated levels of aggregation-prone proteins [141]. It is majorly due to the relatively low expression of chaperones and components of the ubiquitin proteasomal system (UPS), the protein quality control machinery mechanistically integrated with autophagy [142]. ALS-linked mutants of the aggregation-prone RNA-binding proteins (TDP43, FUS, SOD1) and autophagy factors (UBQLN2, OPTN, SQSTM1) aggravate their misfolding to form aggregates and fibrils [143]. Notably, ALS-vulnerable neurons and muscles suffer from excessive or impaired activation of both UPS and autophagy [144, 145]. Cytoplasmic aggregates of ALS-linked mutant proteins act as the ‘nucleation centers’ for subsequent misfolding and aggregation of native proteins that results in their loss of function [143]. Moreover, this generates the compact poly-ubiquitinated inclusion bodies that act as the immuno-histopathological hallmarks of ALS cases.

3.7.1 Hallmark Inclusion Bodies

Ubiquitinated TDP43 aggregates are commonly present in 97% of cases of ALS and 50% of cases of ALS-FTD [146]. These form hyper-phosphorylated skein-like inclusion bodies in the frontal cortex, brain stem, spinal cord, and hippocampus of TARDBP fALS or fALS-FTD and sALS cases [146]. Mutant SOD1 aggregates are known to form fibrillated Lewy bodies and hyaline conglomerate inclusion bodies in SOD1 fALS and sALS cases [147]. FUS aggregates produce basophilic tangle-like inclusion bodies (Bunina bodies) in the spinal cord, motor cortex, and hippocampus of FUS fALS and sALS cases [148]. Interestingly, TDP43 or FUS positive inclusions are not observed in SOD1 fALS cases, although misfolding of SOD1 is triggered in both FUS fALS and TARDBP fALS cases [149]. This suggests a divergent mechanism of misfolding or aggregation across various proteinopathies. Misfolded OPTN and UBQLN2 form skein-like bodies in the frontal cortex and spinal cord in sALS cases and are also found to colocalize with TDP43 and FUS in stress granules [126, 150]. C9ORF72 dipeptide repeats, mainly poly(GA), form ubiquitin-positive bodies in neurons and muscles of C9orf72 fALS-FTD and sALS cases [151]. This can be present with wild-type or misfolded TDP43 aggregates in the cortex and spinal cord or p62 aggregates in the hippocampus and cerebellum [151].

Overexpression or mutation of neurofilament chain proteins, dynein, peripherin, and microtubule-associated protein tau MAPT (reported in ALS-dementia-parkinsonism syndrome) have been found to induce neurofilament aggregation in ALS [7, 152]. Glutamate-induced overexpression of kinases (MAPK, PIN1) induces hyperphosphorylation of neurofilaments that leads to the formation of large perikaryal inclusion bodies and disruption of axonal circuitry [152]. Altogether, the aggregates of misfolded proteins and neurofilaments enforce the global failure of proteasomal and autophagic degradation machinery in ALS.

3.7.2 Dysfunction of Ubiquitin Proteasomal System

In the early stages of ALS, a significant impairment of both total and specific catalytic activity of the ubiquitin proteasomal system (UPS) is usually observed [153]. Furthermore, overexpression of the inducible proteasome subunits occurs early during disease progression, which is followed by the downregulation of the constitutive proteasome subunits [153]. This process is associated with a local inflammatory response mediated by reactive gliosis [154]. While the expression of 26S proteasome is unperturbed in SOD1G93A mice, the levels of 20S proteasome components are specifically decreased in motor neurons of the lumbar spinal cord [155]. Intriguingly, an upregulation of UPS activity underlies the sustained clearance of toxic protein aggregates in the skeletal muscles of SOD1G93A mice. However, excessive activation of UPS results in muscle atrophy through the degradation of myofibrillar proteins and inhibition of myogenesis [156].

Aggregation-prone C9ORF72 dipeptide repeats are known to trigger neurotoxicity by impairing proteasomal activity [151]. ALS-linked mutants of VCP disrupt its interaction with the proteasome and thus impair the proteolysis of bound ubiquitylated substrates [157]. ALS-linked mutants of UBQLN2 induce the accumulation of UBQLN2-positive inclusions, which impair the cargo delivery to the proteasome [158]. Moreover, the downregulation of the proteasomal components triggers the mislocalization and aggregation of ubiquitylated proteins and therefore has been associated with the formation of histopathological marks in ALS [143]. Mutants of cyclin F (CCNF), a component of the E3-ubiquitin ligase complex, induce abnormal accumulation of TDP43 in both fALS and sALS cases [159].

3.7.3 Dysregulation of RNA Metabolism

RNA metabolism and protein synthesis are intricately linked through the activity of dynamic stress granules, and thus there is a concomitant dysregulation of both processes in ALS [160, 161]. ALS-linked mutants of nuclear RNA-binding proteins TDP43, FUS, hnRNPA1, hnRNPA2B1, ATXN2, and matrin 3 (MATR3) form mislocalized cytoplasmic aggregates because of the irreversible interactions with their prion-like low-complexity domains [162]. This alters the assembly and disassembly of ribonucleoprotein granules (SG, P-bodies) that act as nucleation centers for native protein aggregation [161].

By binding to the 3'-UTR of mRNAs, both TDP43 and FUS regulate presynaptic mRNA transport, mRNA splicing, and protein turnover [146, 163]. They also regulate miRNA processing and transport via interaction with the Drosha complex, stabilize long non-coding RNAs, and mediate transcriptional repression of long UG-rich intronic sequences [163]. Mutations in TARDBP occur commonly in the domains involved in protein-protein interaction and nuclear transport, which induces dysregulation of the target transcripts by sequestration in mRNA-silencing foci [164]. These transcripts usually encode RNA-binding proteins (TDP43, FUS, VCP), translation initiation factors (eukaryotic initiation factor EIF2α), microtubule-stabilizing factors (microtubule-associated protein MAP1B), constitutive heat-shock chaperones (heat shock 70 kDa protein cognate 4, i.e., HSC70-4), and neuronal survival proteins (progranulin, choline acetyltransferase) [165].

ALS-linked mutations in FUS occur mostly in the domains carrying the nuclear localization signal and intrinsically disordered regions. Similar to TDP43, such mutants mediate the cytoplasmic mislocalization of FUS [165]. Aggregation of mutant FUS with nucleo-cytoplasmic shuttling proteins (HNRNPA1, HNRNPA2B1), spliceosome assembling proteins (SMN1), and mRNA processing complexes has been found to promote the dysregulation of translatome [166]. Notably, C9orf72 hexanucleotide repeat expansions (HRE) induce defects in nucleo-cytoplasmic shuttling, post-transcriptional processing, ribosomal biogenesis, and assembly of stress granules [160]. RNA foci with transcribed G4C2 repeats of C9orf72 can sequester other RNA-binding proteins [167]. Repeat associated non-AUG (RAN) mediated translation of these transcripts and their anti-sense mRNA can produce toxic dipeptide repeats (DPRs) [168]. Among these DPRs, poly(GA) mainly induces protein aggregation by impairing UPS to trigger ER stress, while poly(GR) and poly(PR) can inhibit global translation by sequestering RNA-binding proteins (FUS, TDP43, ribosomal biogenesis factors) along with their bound transcripts inside stress granules [168].

ALS-linked mutants of the ribonuclease ANG disrupt rRNA transcription and tRNA processing, whereas mutants of the RNA helicase SETX destabilize the transcriptional RNP complexes [7]. Moreover, mutants of other RNA-binding proteins ATXN2, HNRNPA1, HNRNPA2B1, TATA-binding protein associated factor 15 (TAF15), and EWS RNA-binding protein 1 (EWSR1) have been directly associated with ALS pathology [160]. In OPTNE478G fALS cases, the proteotoxic profile resembles that of other proteinopathies involving phosphorylated TDP43, tau, and α-synuclein [169].

Notably, it is a widespread idea in the field that the spread of misfolding and toxic protein aggregates might underlie the course of disease progression (details in Box 3). Development of sensitive assays for the early detection of ALS-relevant misfolded proteins would allow necessary interventions for clearance before they accumulate into large degradation-resistant aggregates and thus prevent the pathological cascade of proteotoxicity.

3.8 Defective DNA Damage Repair System

Defective or toxic DNA damage signalling and repair (DDR), accumulation of endogenous genotoxic stressors (such as ROS), and chromatin disorganization can collectively trigger genomic instability that causes irreversible damage to the terminally differentiated motor neurons. ALS-linked mutants of various cell cycle regulator genes (NEK1, C21ORF2, CCNF) are known to induce abnormalities in DNA damage repair [172]. Mutants of VCP impair DNA damage response through the loss of interaction with non-homologous end-joining repair (NHEJ) factors Ku70/80 and ring finger protein 168 (RNF168) [172]. These defects can be exacerbated by mutants of SQSTM1 through the loss of interaction with other NHEJ factors, such as ataxia telangiectasia mutated (ATM) and RAD50 [172, 173]. In ALS/FTD cases, cytoplasmic mislocalization of TDP43 impairs the nuclear transport of the DNA repair complex of X-ray repair cross-complementing complex 4 (XRCC4) and DNA ligase IV (LIG4), which results in toxic accumulation of DNA double-strand breaks (DSBs) [174]. Additionally, mutant FUS impairs the recruitment of the DNA repair complex XRCC1/LIG3 to DNA single-strand breaks (SSBs) following oxidative damage, which impairs the base excision repair (BER) [175].

Intriguingly, mutant TDP43 and FUS dysregulate DNA: RNA hybrid (R-loop) formation and thus promote transcriptional stress [176]. Transcription of C9orf72 repeat expansions facilitates the accumulation of R-loops as well as the formation of toxic DNA secondary structures, hairpins, and G-quadruplexes [177]. C9orf72 RNA repeat expansion (RRE) foci sequester various RNA‐binding proteins (TDP43, FUS, NPM1, APE1), and thus impairs their DNA damage repair activity [178]. Moreover, dipeptide repeats secreted by C9orf72 fALS astrocytes can trigger genomic instability by sequestering DNA repair factors, inducing R-loop formation, and chromatin compaction [179]. ALS-linked mutants of the R-loop processing factors such as SETX, ATXN2, and HNRNPD are well known [180]. Furthermore, neuronal accumulation of C9ORF72 dipeptide repeats at the nuclear membrane can trigger chromatin disorganization [181]. In both fALS and FTD cases, TBK1 haploinsufficiency leads to chromosomal instability. Cytoplasmic accumulation of ssDNA in ALS-affected neurons over-activates the cyclic GMP/ AMP synthase (cGAS) and stimulator of interferon gene (STING) signaling to trigger a proinflammatory response [182]. Mutants of other ALS-relevant proteins (MATR3, ERBB4), as well as disease modifiers like histone acetyltransferase ELP3, mRNA export factor GLE1, and stress granule component TIA1, have also been found to deregulate DNA damage repair [172].

3.9 Dyshomeostasis of Endoplasmic Reticulum-Mitochondria Functional Networks

Due to the continuous firing of ALS-vulnerable motor neurons (MNs), the chronic depletion of Ca2+ reserves in the endoplasmic reticulum (ER) leads to ER stress [183]. Concurrently, the chronic Ca2+ overload in mitochondria activates pro-apoptotic factors to trigger the release of cell death signals [183]. Loss-of-function mutations in TARDBP and FUS are known to impair autophagosome formation by interfering with ER-Golgi transport and ER-mitochondria interactions. These proteins also compromise mitophagy through the sequestration of the E3 ubiquitin ligase PARKIN [184]. Notably, the dysfunction of selective autophagy contributes to RNA metabolism dysregulation, ER stress, and mitochondrial damage in motor neurons [185]. Accumulation of ROS further inhibits autophagy, stabilises misfolded protein aggregates, and promotes inflammation. This entire loop exacerbates ER stress and mitochondrial damage that results in apoptosis [186].

3.9.1 ER-associated Dysfunction

Astrocytic deletion of membralin, a factor involved in ER-associated degradation (ERAD), facilitates neuronal excitotoxicity [84]. Mutant SOD1 is known to dysregulate the stress granule formation by colocalizing with its core components like RasGTPase-activating protein-binding protein 1 (G3BP1) and T-cell intracellular antigen 1 (TIA1) [187]. At the early symptomatic stage, a selective induction of the PRKR-like ER kinase (PERK) arm of neuronal unfolded protein response (UPR) has been reported [188]. However, this fails to prevent misfolding of mutant proteins due to the naturally low levels of ER-resident chaperones. In transgenic SOD1 mice and sALS patients, the UPR machinery upregulates protein disulphide isomerase (PDI) and other ER-resident chaperones (protein disulphide isomerase PDIA3) in astrocytes and oligodendrocytes [189]. Furthermore, inactive proteins sequestered in stress granules suppress the general translation process and ERAD pathways [190]. Aggregation of mutant VAPB, an integral ER membrane protein, dysregulates the activating transcription factor 6 (ATF6) and X-box binding protein 1 (XBP1) arms of UPR [191]. Despite being an initial adaptive response to ER stress, the prolonged activation of UPR leads to apoptosis [188].

3.9.2 Golgi-associated Dysfunction

ALS-associated mutant proteins can induce Golgi fragmentation by the inhibition of vesicular trafficking in the ER-Golgi and Golgi-plasma membrane networks [192]. Given that the axonal Golgi networks regulate the local synthesis and trafficking of axonal membrane proteins, the Golgi fragmentation can disrupt axonal secretory transport and autophagy [192]. Notably, the fragmentation of somatic and dendritic Golgi precedes axonal retraction and muscle denervation in ALS mouse models [193].

3.9.3 Mitochondrial Dysfunction

In ALS patients, Ca2+ homeostasis is disrupted in the distal dendrites and axons due to the block of mitochondrial transport, with concurrent mitochondrial accumulation in the soma and proximal axon hillock [194]. MNs derived from the spinal cord of ALS patients and presymptomatic SOD1G93A mice show mutant SOD1 aggregates in intermembrane space, mitochondrial swelling, fragmentation of the mitochondrial network, peroxidation of mitochondrial membrane lipids, decreased coupling between mitochondrial oxidative phosphorylation and electron transport chain (ETC), and reduced expression of mitochondrial enzymes [195]. Downregulation of peroxisome proliferator-activated receptor gamma coactivator 1α (PGC-1α), a master regulator of mitochondrial biogenesis and function, exacerbates disease progression across CNS and skeletal muscles of ALS [196]. At the disease onset, dense clusters of presynaptic mitochondria are observed in spinal neurons due to the downregulation of mitochondrial transporter MIRO1 [197]. Moreover, TDP43 inclusion bodies interact with critical mediators of mitochondrial dynamics and mitophagy, such as prohibitin 2 (PHB2) [198]. ALS-linked mutants of VAPB and VCP disrupt the mitochondrial-ER contacts (MERCs) to trigger organellar dysfunction [199]. Dysfunction of mitochondrial complex I and complex V subunits of ETC has been observed in C9orf72 ALS [200].

3.10 Oxidative Stress

In the astrocytes derived from ALS patients and mouse models, there is a decrease in the nuclear factor erythroid 2-related factor 2 (Nrf2)-dependent antioxidant signalling. This is associated with the depletion of glutathione, upregulation of peroxiredoxins and catalase activity, and persistent microglial inflammatory damage to the neighbouring neurons [201]. In the motor cortex, depletion of mitochondrial glutathione reductase (GSH) potentially arises from sustained glutamatergic signalling, and in turn, facilitates mitochondrial Ca2+ release. This leads to dysfunction of the voltage‐dependent anion channel (VDAC) and adenine nucleotide translocator (ANT), along with the opening of apoptotic mitochondrial permeability transition pore (mtPTP) channel in ALS-affected neurons [202]. Mitochondrial ROS accumulation induces glial glutamate release by the upregulation of cysteine-glutamate antiporters, which further promotes oxidative stress due to decreased cysteine uptake [203]. Furthermore, the presynaptic decline at NMJs is facilitated by ROS released by the glial cells and infiltrated immune cells [204]. Cytoplasmic mislocalization of mutant SOD1 impedes the transcription of genes involved in DNA damage response and antioxidant pathways [205]. Mutant TDP43 induces oxidative stress through the nuclear accumulation of Nrf2 and activation of mitochondrial UPR machinery. In turn, oxidative stress promotes GADD34-mediated phosphorylation as well as aggregation of acetylated TDP43 [206]. Mutant FUS inhibits the repair of oxidative stress-mediated DNA damage through defects in DNA ligation [201]. Similar to the ALS-linked mutants of D-amino acid oxidase (DAO) and ALS2 proteins, the toxic dipeptide repeats of C9ORF72 promote ROS generation [172]. Understandably, the exogenous pro-oxidative stress factors such as intense physical activity, radiation, metal toxicity etc., as well as endogenous modifiers such as malnutrition, cachexia, respiratory weakness etc., can exacerbate the disease progression in ALS [207].

3.11 Dysregulation of Metabolic Programming

Rapid cycles of action potential propagation and presynaptic transport across the long axon of fast-firing motor neurons are major factors for the high energy demand of CNS [37, 208]. Moreover, high ATP levels are required to prevent the aggregate formation in both soma and axon [209]. Neuronal energy homeostasis is linked with the antioxidant glutathione machinery through a fine balance between the glycolytic and pentose phosphate pathway (PPP) flux [210]. High metabolic demand and low oxidative stress response of corticospinal neurons and skeletal muscles render them selectively vulnerable to the energy defects in ALS. This impairs self-regenerative pathways, which facilitates terminal nerve retraction and loss of reinnervation [211]. In order to produce in situ energy substrates during impaired neuronal glucose uptake, ROS generated by the mitochondrial ETC system stimulates lipid transport to astrocytes, which otherwise accelerates neurodegeneration [212].

In ALS patients with pure UMN involvement, positron emission tomography (PET) imaging using 2-deoxy-2-fluoro-D-glucose (18FDG) revealed glucose hypo-metabolism across the fronto-dorsolateral cortex, precentral cortex, and temporal cortex [213]. However, a diverse glucose hyper-metabolism pattern is found in the midbrain, spinal cord, and skeletal muscles of ALS patients [214, 215]. Severe metabolic impairment occurs in the precentral gyrus during the bulbar onset and in the cervical cord during the upper limb onset [214]. Therefore, diverse states of metabolic pathogenicity occur spatiotemporally across CNS during the disease progression. In SOD1G93A mice, glucose uptake in the spinal cord increases at the presymptomatic stage, but it declines progressively [216]. In the spinal cord of end-stage ALS patients and SOD1G93A mice, the uncoupling of blood flow and glucose metabolism is observed with a concomitant increase in glycogen storage [217]. There is a persistent downregulation of glycolysis rate-limiting enzyme phosphofructokinase 1 (PFK1), Kreb's cycle enzyme succinate dehydrogenase (SDH), and Kreb's cycle intermediates in the CNS and skeletal muscles [218, 219]. Interestingly, impaired neuronal glucose oxidation has been associated with unperturbed astrocytic Kreb’s cycle at symptomatic stages in SOD1G93A mice [220]. Dysregulation of nucleotide metabolism and histidine metabolism during ALS progression might serve as a metabolic signature of pervasive DNA damage by oxidative stress [180].

3.11.1 ‘Hyper’ Metabolism in ALS

Systemic hypermetabolism, accompanied by dyslipidaemia, has been reported at the presymptomatic stage in ALS patients and SOD1G93A mice [221]. The shift from glucose-dependent to lipid-based metabolism may be an adaptive response against the disrupted energy homeostasis at early stages [222]. Ketosis in astroglia promotes the reuptake of extracellular glutamate and induces the synthesis of GABA from glutamine in neurons [223]. Notably, endogenous energy reserves of skeletal muscles and adipose tissues are progressively depleted during the course of the disease. As a result, ALS patients often develop insulin resistance due to the dysregulated glycogen metabolism in muscles [224]. Proteomic analysis of motor neurons from SODG93A mice revealed the upregulation of hydroxy acyl-CoA dehydrogenase subunit A (HADHA) and acetyl-CoA acetyltransferase 2 (ACAT2) enzymes involved in ketosis, and β-hydroxy β-methyl glutaryl-CoA (HMG-CoA synthase) involved in cholesterol metabolism [225]. Interestingly, lipid accumulation during ALS progression is independent of the downregulation of enzymatic and transcriptional regulators of lipid synthesis [226].

In the spinal cord of transgenic SOD1G86R mouse, inhibition of β-glucocerebrosidase is found to promote glycosphingolipid metabolism, which delays ALS onset by inducing muscle reinnervation [227]. Interestingly, the ganglioside GM1a interacts with the BDNF receptor TrkA and with the Na+/Ca2+ exchanger at the nuclear membrane to facilitate Ca2+ transfer to ER [228]. Towards later stages, prolonged lipid hypermetabolism promotes oxidative stress via the by-products of ketosis and cholesterol synthesis in the spinal cord and skeletal muscles [226]. Notably, the progressive decrease of membrane fluidity observed in ALS mouse models can be attributed to the increased peroxidation of polyunsaturated fatty acids, which generates excitotoxic intermediates like 4-hydroxynonenal, and inflammatory mediators like eicosanoids [229]. Moreover, the excessive production of cholesterol and sphingolipids impairs vesicular transport, neurotransmitter cycling, and cytoskeletal organization and triggers excitotoxicity through defective RNA editing of GLUR2 transcript in neurons [230]. This process disrupts the ‘cholesterol sensor’ LXR signalling, which induces apoptosis [231].

Multiple pilot clinical trials have suggested that a high-fat diet can improve prognosis and delay disease progression in ALS patients by promoting LDL/HDL ratios or body mass index [232]. Importantly, approaches that target various steps of the neuroglial glucose metabolism might have potential in ALS therapy [218]. Fig. (3) provides an overview of the non-cell autonomous and cross-talking pathogenic processes across the neuroglial networks and neuromuscular junctions affected in ALS.

4 GENE & ENVIRONMENT: EPIGENETIC & EPITRANSCRIPTOMIC LANDSCAPE IN ALS

Only ~30 environmental risk factors have been significantly associated with ALS incidence till date through summary statistics from genome-wide association studies, linkage disequilibrium score regression, and Mendelian randomization analyses [16]. These factors include intense physical activity, psychiatric disorders, military service, contact sports, comorbid diseases (Type I diabetes, viral infections), and exposure to neurotoxins, heavy metals and organic solvents [233]. As per the gene-environment-time interaction (GETI) hypothesis of ALS incidence, a genetic risk variant can interact with a combination of environmental risk factors at a specific age in a particular geographical region for a definite period of time [16]. A panel of inherited genetic defects with varying penetrance might differentially trigger the primary pathogenic pathway. It needs to be complemented by variable intensities and combinations of environmental triggers to affect the secondary pathways that cumulatively set off the pathological cascade for ALS onset [234].

Epigenetic modifications involve the reversible heritable or non-heritable alterations in gene expression without any changes to the genome sequence, in response to endogenous and environmental factors [235]. Changes in the epitranscriptome (RNA epigenetics) reveal a novel code of locus and cell type-specific modifications on different classes of RNA for a dynamic and rapid co-transcriptional and post-transcriptional regulation of RNA expression, stability, localization, and function [236].

4.1 Epigenetic Signatures in ALS

In spinal LMNs of sALS and C9orf72 fALS patients, immunohistochemical studies revealed an increase in methylation and hydroxymethylation of CpG islands at gene promoters, which inversely correlated with TDP43 pathology [237]. Quantitative analyses of methylation profiles depicted that 5’-hydroxymethylcytosine (5hmC) levels are increased in corticospinal motor neurons of hSOD1G93A mice and decreased in prpTDP43A315T mice [238]. Repeat-primed and methylation-specific PCR revealed hypermethylation of CpG islands near the C9orf72 repeat expansions in blood and brain samples from 10-30% of ALS and FTD cases [239]. Notably, increased 5’-methylcytosine (5mC) levels in mitochondria (especially at 16S rRNA gene) and downregulation of DNA methyltransferase DNMT3A, associated with mitophagy, were reported in skeletal muscles and spinal motor neurons of transgenic SOD1 mice [240].

In ALS patients, deficiency of the histone acetyltransferase (HAT) elongator acetyltransferase complex subunit 3 (ELP3) leads to a decrease in the transcriptional activation acetylation marks on lysine 14 of histone H3 (H3K14ac) and lysine 8 of histone H4 (H4K8ac) [241]. In SOD1G93A mice, inhibition of the histone deacetylase HDAC6 at early stages increases α-tubulin and TDP43 acetylation, while HDAC6 overexpression at late stages promotes autophagy [242, 243]. In skeletal muscles of SOD1G93A mice and ALS patients with rapid disease progression, HDAC4 is upregulated at presymptomatic stages and protects from skeletal muscle atrophy but is decreased upon symptom onset [244]. In primary cultures of spinal motor neurons of transgenic FUSR495X mice, downregulation of protein arginine N-methyl transferase 1 (PRMT1) is associated with a decrease in asymmetric di-methylation on arginine 3 of histone H4 (H4R3me2asym), with concomitant downregulation of H3K9ac and H3K14ac marks [245]. ALS-linked TDP43M337V and FUSR495X mutants have been found to reduce the global levels of conjugate H3 phosphorylation at serine 10 and acetylation at lysine 14 (H3S10Ph-K14Ac), which in turn dysregulates NF-κB signalling [246]. Distinct alteration patterns of the cross-talking histone methylation and histone acetylation marks suggest that each proteinopathy dictates its distinct histone modification landscape to converge on the pathological hallmarks of ALS.

Despite a wide variety of studies regarding miRNA deregulation in ALS patients, there is a limited overlap of the miRNA signatures, possibly because of the variation in study populations, types of control subjects, disease stages, sample sources, methods of tissue extraction, and miRNA expression profiling [247]. A recent meta-analysis of all available studies on miRNA dysregulation in ALS has identified four miRNAs (hsa-miR-9-5p/3p, hsa-miR-28-5p/3p, hsa-miR-132-5p/3p, hsa-miR-146a-5p/3p) to be the most commonly reported across nervous tissue, cerebrospinal fluid, skeletal muscles, and plasma or blood or serum [248]. A competitive endogenous circRNA-miRNA-mRNA axis reported in ALS involves the circRNA hsa-circ-0023919 that inhibits miR-9, which otherwise regulates the transcription of intermediate filament NEFL and leads to neurofilament aggregation [249].

4.2 Epitranscriptomic Landscape of ALS

Molecular heterogeneity in ALS etiopathogenesis can potentially be attributed to aberrant RNA modifications on various RNA substrates or a modification-independent function of the RNA modifiers [250]. In the spinal cord of ALS patients and transgenic SOD1 mice, accumulation of oxidized mRNA species bearing 8-oxo-7,8-dihydroguanosine (8OHG) has been consistently observed [251]. Oxidation of mRNA species has been primarily found in motor neurons and oligodendrocytes at the early presymptomatic stage, before the oxidation of lipids, proteins, and DNA during the symptomatic stage [251]. Post-transcriptional adenine-to-inosine (A-to-I) RNA editing at the glutamine/arginine (Q/R) site in GluA2, a subunit of glutamate receptor GluR2, is essential to prevent excitotoxicity in spinal motor neurons of sALS patients [252]. Upon conditional knockout of the RNA editing enzyme adenosine deaminase acting on RNA 2 (ADAR2) in mice, the motor neurons expressing Q/R site-unedited GluA2 subunit undergo apoptosis due to calcium overload and dysregulated autophagy [253]. The mislocalization of ADAR2 has been reported in the motor cortex and lumbar spinal cord of C9orf72 ALS/FTD patients [254].

Through the technique of methylated RNA immunoprecipitation with sequencing (MeRIP-seq), a global decrease in the level of N6-methyladenosine (m6A) modification on RNA has been observed upon TARDBP knockdown in mammalian cells [255]. This phenomenon is similar to that observed upon silencing of the m6A writer METTL3, which regulates synaptic growth at neuromuscular junctions [255]. Interestingly, mutations in the m6A reader hnRNPA2B1, which also regulates proteostasis, have been frequently associated with ALS [256]. Whole-genome sequencing revealed a positive association of motor neuron-specific variants in fat mass and obesity-associated protein (FTO), an m6A eraser factor from the α-ketoglutarate dependent dioxygenase family, with sALS cases [257]. Upon the loss of site-specific m5C modifications during cellular stress, the ALS-associated ribonuclease ANG promotes the cleavage of tRNAs to generate tRNA-derived small RNAs (tsRNAs) and triggers the assembly of stress granules [258]. Deregulation of the RNA methyltransferase DNMT2, which otherwise prevents tsRNA accumulation has been observed in FUS fALS cases with a concomitant increase in 5mC mark on the proximal FUS promoter, a lower FUS expression and a higher cytoplasmic FUS aggregation in motor neurons [259]. Notably, accumulation of 5’ValCAC tRNA fragment (valine tRNA with CAC anticodon) with increased ANG expression has been reported in the spinal cord and serum from SOD1G93A mice at the symptom onset [260]. A recently discovered hallmark of ALS-FTD cases involves the nuclear depletion and cytoplasmic accumulation of the neuronal-enriched splicing factor SFPQ, which produces aberrant intron-retaining (IR) transcripts of neuronal proteins for accumulation in RNA granules at neurites [261]. A broad overview of commonly reported epigenetic and epitranscriptomic signatures of ALS pathogenesis is given in Fig. (4).

5 CHALLENGES AND PROSPECTS FOR ALS PATHOMECHANISTIC RESEARCH

The Food and Drug Administration (FDA) has currently approved very few drugs, namely Riluzole, Edaravone, and NueDexta, that can only moderately improve survival across specific ALS patient populations. Widespread efforts for treatments targeting the pathomechanistic networks of ALS have led to several late-stage clinical trials, with the primary therapeutic target being neuroinflammatory pathways (particularly the complement system) followed by oxidative and proteotoxic stress response [262]. These involve inhibitor molecules, genetic therapies through antisense oligonucleotides (ASO), stem-cell-based therapies, and recombinant humanized monoclonal antibodies [263]. Notably, the tyrosine kinase inhibitor Masitinib has been reported to prolong survival in phase III clinical trials by targeting macrophages, mast cells, and microglia [264]. For a detailed review of previously tested and failed treatment strategies, and novel therapeutics (including the repurposing of available drugs) in the pipeline, the readers can refer to Corcia et al. 2021 [263] and Mead et al. 2023 [262].

5.1 Broader Relevance of Pre-clinical Models

The corticospinal tract in rodents runs through the dorsal funiculi and ends at the dorsal horn, as opposed to the direct ventral connections in humans [265]. ALS models of non-primates show early corticomotor hyperexcitability, which modulates LMN dysfunction through the local oligosynaptic and excitatory inter-neuronal networks [266]. It is important to use a range of complex disease models, including patient fibroblast-derived neural progenitor differentiation systems, and monitor the same prognostic phenotype marker from disease models to clinical trials.

5.2 Stage-specific Non-cell Autonomous Phenotypes

In-depth methodological analysis and holistic integration of epidemiological and clinicopathological data from patient cohorts can help to characterize common and divergent mechanisms in ALS pathophysiology. Modulation of the activity of γ-MNs, Renshaw cells, or metabotropic GluRs with the help of inhibitory ‘designer receptors exclusively activated by designer drugs’ (DREADDs) might be useful in targeting the neuronal microcircuit dysfunction in ALS [61]. Notably, the lack of selectivity and efficacy of the autophagy-inducer drugs tested for ALS therapy makes it necessary to elucidate the site and the stage-specific window of dysfunction [109]. Disaggregases like heat shock proteins HSP27 and HSPB1 can regulate phase separation and liquid-to-gel transition of accumulated TDP43 or stress granule protein G3BP1 condensates in axons and NMJs [267]. The use of 3D microfluidic system models for the stratification of heterogeneous non-neuronal phenotypes may provide new therapeutic targets to combat the non-cell autonomous pathogenicity in ALS [71].

It is sensible to design novel therapies that either target the inhibition of degenerative factors selectively active in ALS-vulnerable motor neurons and myofibres or the activation of intrinsic neuroprotective defence factors expressed in their resilient counterparts [52]. In the early stages of ALS, the synaptic hyperexcitability overactivated BDNF/TrkB signaling, which can be prevented by the inhibition of the adenosine 2A receptor (A2aR) that transactivates TrkB [268]. Development of high-resolution techniques that account for spatial subdivision of metabolic identities across heterogeneous cellular networks is required for the ‘precision medicine’ research in ALS. Machine learning techniques can prove useful in the identification of biomarkers of target engagement as well as disease progression [269].

5.3 Stratification of Sporadic Cases

There is a need for integration of the effect of genome, exposome, and behavome on the spatiotemporal patterns of health outcomes across populations. This brings in the concept of genetic geographic information science (Genetic GISc) [270]. Variations in the neuroendocrine stress response can influence the clinical heterogeneity of ALS in a vulnerable genetic, constitutional, or epigenetic background [271].

5.4 Role of Hormetic Dose Response in Pathology

An interesting hypothesis of ALS pathogenecity posits that the accumulation of age-associated oxidative damage accounts for the late onset and slow progression of neurodegenerative disorders [272]. Mild exposure to environmental stressors activates the adaptive stress response pathways involving the vitagene network, through a central redox-sensing thiol-modifying signalling, for the synthesis of stress-resistance proteins [273]. This integrated response protects the biological system from severe exposure in the future and constitutes the biphasic ‘preconditioning’ or ‘hormetic’ response [274]. Intriguingly, improvement of prognosis in SOD1G93A mice observed upon exposure to a sub-toxic dose of neurotoxin β-methylamino-L-alanine (L-BMAA) suggests that variation in exposure to an environmental risk factor can be neuroprotective or neurotoxic in the context of a genetic predisposition [275]. Sustained activation of NMDAR leads to prolonged stimulation of NOS, generation of superoxide or peroxynitrite anions, nitric oxide (NO) mediated S-nitrosylation of survival proteins (e.g., MMP9, PDI, COX) and glutamate release-associated synaptic vesicle proteins [272]. However, physiological levels of NO promote survival by nitrosylating NMDAR and Caspase-3 subunits with activation of Akt kinase and CREB signalling [272]. The adaptive nature of hormetic dose responses provides a quantitative index of the plasticity of biological systems irrespective of gender, biological model, timepoint, nature of the agent, or type of induction [274]. To combat both acute and chronic neurodegenerative diseases, the low-dose response stimulation of ER stress and antioxidant pathways can be targeted through dietary restriction or chemically modified drugs [273]. Nutraceuticals such as hydroxytyrosol (Hidrox®) can be promising in ALS therapy since it modulates the Nrf2-regulated hemeoxygenase-1 (HO-1) pathway, NF-κB signalling, and sirtuin signalling [276]. Moreover, resveratrol, an activator of SIRT1-FOXO signalling and Keap1-Nrf2 signalling, is known to be neuroprotective in experimental ALS models [277]. The range estimation of stimulatory hormetic dose responses can be used to improve the quantitative design of a clinical study, which increases the probability of inducing an optimal response across the heterogenous patient subgroups [278].

5.5 Epigenetic and Epitranscriptomic Precision Research

Novel techniques to detect disease-associated epigenetic marks include methylcytosine-capture DNA hybridization immunoassay for semi-quantitative detection of the repeat methylation levels, especially for the diagnosis of C9orf72 repeat expansion carriers [279]. Notably, a recent study demonstrated direct in vivo non-invasive spatial profiling of DNA methylation in mouse brains through a novel 13C tracer-based magnetic resonance spectroscopic imaging (13C-MRSI) method [280]. Regarding ALS epigenetic therapy, research should now be directed toward drugs targeting DNA and histone methylation modifiers and histone phosphorylases. Inhibition of protein phosphatase 1, which erases the H3S10ph mark, can be studied as a potential therapeutic target [281]. Recently, FDA has approved AMX0035 (Relyvrio or Albrizo) for ALS treatment, a combination of taurursodiol and the pan-HDAC inhibitor sodium phenylbutyrate (4-PB), which rescues from ER stress and mitochondrial dysfunction [282]. However, large-scale clinical trials for epigenetic modifier drugs is limited, given the opposing nature of epigenetic modifier activity during ALS and the risk of off-target effects [283].

A bidirectional dCasRx epitranscriptome editing platform composed of a nuclear-localized dCasRx conjugated with methyltransferase or demethylase is currently used to discern the molecular function of individual site-specific m6A modifications or modifiers [284]. RNA metabolism defects have been successfully reversed by CRISPR-Cas9 targeting of repeat expansions in C9orf72 fALS patient cells [285]. Given the cross-talk between epigenetic and epitranscriptomic signatures, it would be prudent to design ‘precision medicine’ regimens for sALS patient subgroups with a defined genetic makeup and exposome.

Questions for Future Research

How do the shared and unique molecular networks of pathogenicity determine a longer survival in ALS cases involving the male gender, spinal form of onset, younger age at onset or diagnosis, and a higher baseline score on the revised ALS Functional Rating Scale (ALSFRS-R) or the Rasch-built Overall ALS Disability Scale (ROADS)?

How can different environmental factors influence common metabolic pathways to induce changes in the epigenetic or epitranscriptomic landscape in a tissue or cell-specific manner?

Rather than simple association studies, interactions between cellular processes and molecular networks need to be considered for combination therapy or targeting upstream regulators in complex neurodegenerative disorders like ALS.

CONCLUSION

ALS entails a complex genetic architecture that is oligogenic or polygenic in sporadic cases and mostly monogenic in familial cases. Secondary oligogenic variants with low allele frequency have uncertain or varying effect sizes in the presence of a highly penetrant primary variant, which might result in the pleiotropy of phenotype [286]. Based on various large-scale epidemiological studies, the ALS phenotype has been regarded as the culmination of a six-step process of pathogenesis, with a lesser number of pathogenesis-relevant steps in patient cohorts with large-effect genetic variants (SOD1, C9ORF72) [287]. The disease endophenotype is the end result of the interaction between inherited genetic risk factors and a combination of environmental and endogenous risk factors. The genetic architecture of ALS can be partitioned into distinct risk-associated components rather than simply fALS or sALS, which in turn can facilitate the validation of pathological mechanisms and the stratification of patient sub-groups. The combinatorial effect of interactions between various ALS-linked genetic variants and environmental risk factors can regulate pathogenesis in a synergistic or antagonistic manner [16, 287].

ACKNOWLEDGEMENTS

Figures were created with the help of BioRender.

AUTHORS’ CONTRIBUTIONS

Bedaballi Dey conceived the idea for the article, performed the literature survey, and wrote the first draft of the manuscript. Anant Bahadur Patel conceived the idea for the article, critically revised and made final editing to the work. Arvind Kumar conceived the idea for the article, critically revised and made final editing to the work. All authors read and approved the final manuscript.

LIST OF ABBREVIATIONS

ALS Amyotrophic Lateral Sclerosis

AMPA α-Amino-3-hydroxy-5-Methyl-4-isoxazole propionic acid

BDNF Bone Derived Neurotrophic Factor

CSF Cerebro Spinal Fluid

fALS Familial ALS

G3BP1 RasGTPase-activating Protein-binding Protein 1

IFN Interferon

MN Motor Neuron

mTOR Mammalian Target of Rapamycin

NF-κB Nuclear Factor Kappa B

NMDA N-Methyl-D-Aspartic Acid

NMJ Neuro Muscular Junction

PGC-1α Peroxisome Proliferator-activated Receptor Gamma Coactivator 1α

sALS Sporadic ALS

TIA1 T-cell Intracellular Antigen 1

TNF-α Tumour Necrosis Factor α

CONSENT FOR PUBLICATION

Not applicable.

FUNDING

This work was supported by funding from the Cognitive Science Research Initiative Program under the Department of Science and Technology (DST), Govt. of India (DST/CSRI/2017/258) and by a Senior Researcher fellowship to BD from the Department of Biotechnology (DBT), Govt. of India (DBT/JRF/BET-17/1/2017/AL/400).

CONFLICT OF INTEREST

The authors declare no conflict of interest, financial or otherwise.

Fig. (1) Pattern of the motor system dysfunction in ALS. Progressive degeneration affects the vulnerable fast-fatigable (FF) motor neurons and type IIb myofibres. Slow twitch (S) motor neurons and type I myofibres are resilient until the end stages. A ‘dying forward’ hypothesis proposes an anterograde degenerative trigger from cortex progresses towards spinal cord through trans-synaptic glutamate excitotoxicity. LMNs without a monosynaptic connection to corticomotor neurons are resilient to ALS pathology such as oculomotor, abducens, trochlear nerve, and Onuf's nuclei. A ‘dying back’ hypothesis suggests that an early retrograde degeneration trigger from neuromuscular junctions (NMJs) moves back towards primary motor cortex by distal axonopathy. Both UMN and LMN degeneration can also occur independently and in a stochastic manner during ALS progression, which might be attributed to oxidative stress mediated apoptosis. Reprinted from N Engl J Med 377:2, Brown, R.H.; Al-Chalabi, A., Amyotrophic Lateral Sclerosis, 162-172, Copyright (2017), with permission from (Massachusetts Medical Society).

Fig. (2) Complex interplay of molecular networks in ALS pathogenesis. Mislocalization and aggregation of misfolded proteins dysregulate RNA metabolism as well as stress granule dynamics, which in turn induces endoplasmic reticulum stress, oxidative stress, mitochondrial dysfunction, and DNA damage. Overexpression of Ca2+ -permeable glutamate receptors in postsynaptic neurons, and increased glutamate release by presynaptic neurons and astrocytes is associated with decreased glutamate reuptake from synapse. Concomitant synaptic stripping of the inhibitory connections triggers sustained neuronal firing that results in excitotoxicity. Chemokines released from the affected neurons and reactive astroglia promote necroptosis of oligodendrocytes with subsequent demyelination.

Fig. (3) A multi-network and non-cell autonomous failure of cellular homeostasis processes drives ALS. Misfolded protein aggregates induce defects in the intracellular homeostasis processes, which in turn disrupts the protective neuron-astroglia crosstalk. Concomitantly, the defects in synaptic scaling and plasticity of motor neurons results in glutamate excitotoxicity. Release of neuron-specific antigens and proinflammatory stimuli primes T-helper cells into a proinflammatory Th17 phenotype for recruitment into the central nervous system. Side by side, infiltration of cytotoxic T-cells and natural killer cells occurs through adaptive immune signalling. Defective axonal transport hinders the cholinergic transmission towards neuromuscular junctions and impairs myofibre contractility. Release of growth-cone repellents from skeletal muscles and chemorepellents from dying terminal Schwann cells triggers distal axonopathy.

Fig. (4) Changes in the epigenetic and epitranscriptomic landscape during ALS pathogenesis. ALS-associated epigenetic signatures include a global increase in DNA methylation with a concomitant deregulation of DNA methyltransferases (DNMTs). A global decrease in histone acetylation is concomitant with a dysregulation of histone acetyltransferases and histone deacetylases (HDACs). Global dysregulation of miRNA levels includes their sequestration in stress granules by mutant protein aggregates. ALS-relevant epitranscriptomic modifications commonly involves A-to-I editing defect in GluA2 transcript, which upregulates Ca2+ -permeable glutamate receptor in neurons. Accumulation of ROS-induced oxidized mRNA species, and tRNA fragment cleaved by mutant ANG impairs protein translation efficiency. Aberrant intron-retaining transcripts promote mislocalization of RNA binding proteins. Abbreviations: CHD2: chromodomain DNA helicase protein 2; CBP/p300: CREB binding protein p300; EAAT2: excitatory amino acid transporter 2; nBAF: neuronal Brg1-associated factor; PRMT1: protein arginine methyltransferase 1; SIRT: sirtuin; SFPQ: splice factor proline glutamine rich.
==== Refs
REFERENCES

1 Checkoway H. Lundin J.I. Kelada S.N. Neurodegenerative diseases. IARC Sci. Publ. 2011 163 407 419 22997874
2 Logroscino G. Piccininni M. Marin B. Nichols E. Abd-Allah F. Abdelalim A. Alahdab F. Asgedom S.W. Awasthi A. Chaiah Y. Daryani A. Do H.P. Dubey M. Elbaz A. Eskandarieh S. Farhadi F. Farzadfar F. Fereshtehnejad S-M. Fernandes E. Filip I. Foreman K.J. Gebre A.K. Gnedovskaya E.V. Hamidi S. Hay S.I. Irvani S.S.N. Ji J.S. Kasaeian A. Kim Y.J. Mantovani L.G. Mashamba-Thompson T.P. Mehndiratta M.M. Mokdad A.H. Nagel G. Nguyen T.H. Nixon M.R. Olagunju A.T. Owolabi M.O. Piradov M.A. Qorbani M. Radfar A. Reiner R.C. Sahraian M.A. Sarvi S. Sharif M. Temsah O. Tran B.X. Truong N.T. Venketasubramanian N. Winkler A.S. Yimer E.M. Feigin V.L. Vos T. Murray C.J.L. Global, regional, and national burden of motor neuron diseases 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018 17 12 1083 1097 10.1016/S1474-4422(18)30404-6 30409709
3 Longinetti E. Fang F. Epidemiology of amyotrophic lateral sclerosis: an update of recent literature. Curr. Opin. Neurol. 2019 32 5 771 776 10.1097/WCO.0000000000000730 31361627
4 Grad L.I. Rouleau G.A. Ravits J. Cashman N.R. Clinical spectrum of amyotrophic lateral sclerosis (ALS). Cold Spring Harb. Perspect. Med. 2017 7 8 a024117 10.1101/cshperspect.a024117 28003278
5 Abramzon Y.A. Fratta P. Traynor B.J. Chia R. The overlapping genetics of amyotrophic lateral sclerosis and frontotemporal dementia. Front. Neurosci. 2020 14 42 10.3389/fnins.2020.00042 32116499
6 Masrori P. Van Damme P. Amyotrophic lateral sclerosis: A clinical review. Eur. J. Neurol. 2020 27 10 1918 1929 10.1111/ene.14393 32526057
7 Ferraiuolo L. Kirby J. Grierson A.J. Sendtner M. Shaw P.J. Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis. Nat. Rev. Neurol. 2011 7 11 616 630 10.1038/nrneurol.2011.152 22051914
8 Manjaly Z.R. Scott K.M. Abhinav K. Wijesekera L. Ganesalingam J. Goldstein L.H. Janssen A. Dougherty A. Willey E. Stanton B.R. Turner M.R. Ampong M.A. Sakel M. Orrell R.W. Howard R. Shaw C.E. Leigh P.N. Al-Chalabi A. The sex ratio in amyotrophic lateral sclerosis: A population based study. Amyotroph. Lateral Scler. 2010 11 5 439 442 10.3109/17482961003610853 20225930
9 Palese F. Sartori A. Verriello L. Ros S. Passadore P. Manganotti P. Barbone F. Pisa F.E. Epidemiology of amyotrophic lateral sclerosis in Friuli-Venezia Giulia, North-Eastern Italy, 2002–2014: A retrospective population-based study. Amyotroph. Lateral Scler. Frontotemporal Degener. 2019 20 1-2 90 99 10.1080/21678421.2018.1511732 30430867
10 Leighton D.J. Newton J. Stephenson L.J. Colville S. Davenport R. Gorrie G. Morrison I. Swingler R. Chandran S. Pal S. Changing epidemiology of motor neurone disease in Scotland. J. Neurol. 2019 266 4 817 825 10.1007/s00415-019-09190-7 30805795
11 Chiò A. Logroscino G. Traynor B.J. Collins J. Simeone J.C. Goldstein L.A. White L.A. Global epidemiology of amyotrophic lateral sclerosis: A systematic review of the published literature. Neuroepidemiology 2013 41 2 118 130 10.1159/000351153 23860588
12 Hardiman O. Al-Chalabi A. Brayne C. Beghi E. van den Berg L.H. Chio A. Martin S. Logroscino G. Rooney J. The changing picture of amyotrophic lateral sclerosis: Lessons from European registers. J. Neurol. Neurosurg. Psychiatry 2017 88 7 557 563 10.1136/jnnp-2016-314495 28285264
13 Brooks B.R. Miller R.G. Swash M. Munsat T.L. El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 2000 1 5 293 299 10.1080/146608200300079536 11464847
14 van den Berg L.H. Sorenson E. Gronseth G. Macklin E.A. Andrews J. Baloh R.H. Benatar M. Berry J.D. Chio A. Corcia P. Genge A. Gubitz A.K. Lomen-Hoerth C. McDermott C.J. Pioro E.P. Rosenfeld J. Silani V. Turner M.R. Weber M. Brooks B.R. Miller R.G. Mitsumoto H. Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials. Neurology 2019 92 14 e1610 e1623 10.1212/WNL.0000000000007242 30850440
15 Shefner J.M. Al-Chalabi A. Baker M.R. Cui L.Y. de Carvalho M. Eisen A. Grosskreutz J. Hardiman O. Henderson R. Matamala J.M. Mitsumoto H. Paulus W. Simon N. Swash M. Talbot K. Turner M.R. Ugawa Y. van den Berg L.H. Verdugo R. Vucic S. Kaji R. Burke D. Kiernan M.C. A proposal for new diagnostic criteria for ALS. Clin. Neurophysiol. 2020 131 8 1975 1978 10.1016/j.clinph.2020.04.005 32387049
16 Bradley W.G. Andrew A.S. Traynor B.J. Chiò A. Butt T.H. Stommel E.W. Gene-environment-time interactions in neurodegenerative diseases: Hypotheses and research approaches. Ann. Neurosci. 2018 25 4 261 267 10.1159/000495321 31000966
17 Rossi F.H. Pathophysiology of Amyotrophic Lateral Sclerosis. Rijeka IntechOpen 2013 10.5772/56562
18 Schweingruber C. Hedlund E. The cell autonomous and non-cell autonomous aspects of neuronal vulnerability and resilience in amyotrophic lateral sclerosis. Biology 2022 11 8 1191 10.3390/biology11081191 36009818
19 Turner M.R. Hardiman O. Benatar M. Brooks B.R. Chio A. de Carvalho M. Ince P.G. Lin C. Miller R.G. Mitsumoto H. Nicholson G. Ravits J. Shaw P.J. Swash M. Talbot K. Traynor B.J. Van den Berg L.H. Veldink J.H. Vucic S. Kiernan M.C. Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurol. 2013 12 3 310 322 10.1016/S1474-4422(13)70036-X 23415570
20 Mejzini R. Flynn L.L. Pitout I.L. Fletcher S. Wilton S.D. Akkari P.A. ALS genetics, mechanisms, and therapeutics: Where are we now? Front. Neurosci. 2019 13 1310 10.3389/fnins.2019.01310 31866818
21 Ryan M. Heverin M. McLaughlin R.L. Hardiman O. Lifetime risk and heritability of amyotrophic lateral sclerosis. JAMA Neurol. 2019 76 11 1367 1374 10.1001/jamaneurol.2019.2044 31329211
22 Fifita J.A. Williams K.L. Sundaramoorthy V. Mccann E.P. Nicholson G.A. Atkin J.D. Blair I.P. A novel amyotrophic lateral sclerosis mutation in OPTN induces ER stress and Golgi fragmentation in vitro. Amyotroph. Lateral Scler. Frontotemporal Degener. 2017 18 1-2 126 133 10.1080/21678421.2016.1218517 27534431
23 Brown C. Non-Familial ALS: A tangled web. Nature 2017 550 7676 S109 S111 10.1038/550S109a 29045373
24 Cooper-Knock J. Harvey C. Zhang S. Moll T. Timpanaro I.S. Kenna K.P. Iacoangeli A. Veldink J.H. Advances in the genetic classification of amyotrophic lateral sclerosis. Curr. Opin. Neurol. 2021 34 5 756 764 10.1097/WCO.0000000000000986 34343141
25 van Rheenen W. van der Spek R.A.A. Bakker M.K. van Vugt J.J.F.A. Hop P.J. Zwamborn R.A.J. de Klein N. Westra H.J. Bakker O.B. Deelen P. Shireby G. Hannon E. Moisse M. Baird D. Restuadi R. Dolzhenko E. Dekker A.M. Gawor K. Westeneng H.J. Tazelaar G.H.P. van Eijk K.R. Kooyman M. Byrne R.P. Doherty M. Heverin M. Al Khleifat A. Iacoangeli A. Shatunov A. Ticozzi N. Cooper-Knock J. Smith B.N. Gromicho M. Chandran S. Pal S. Morrison K.E. Shaw P.J. Hardy J. Orrell R.W. Sendtner M. Meyer T. Başak N. van der Kooi A.J. Ratti A. Fogh I. Gellera C. Lauria G. Corti S. Cereda C. Sproviero D. D’Alfonso S. Sorarù G. Siciliano G. Filosto M. Padovani A. Chiò A. Calvo A. Moglia C. Brunetti M. Canosa A. Grassano M. Beghi E. Pupillo E. Logroscino G. Nefussy B. Osmanovic A. Nordin A. Lerner Y. Zabari M. Gotkine M. Baloh R.H. Bell S. Vourc’h P. Corcia P. Couratier P. Millecamps S. Meininger V. Salachas F. Mora Pardina J.S. Assialioui A. Rojas-García R. Dion P.A. Ross J.P. Ludolph A.C. Weishaupt J.H. Brenner D. Freischmidt A. Bensimon G. Brice A. Durr A. Payan C.A.M. Saker-Delye S. Wood N.W. Topp S. Rademakers R. Tittmann L. Lieb W. Franke A. Ripke S. Braun A. Kraft J. Whiteman D.C. Olsen C.M. Uitterlinden A.G. Hofman A. Rietschel M. Cichon S. Nöthen M.M. Amouyel P. Comi G. Riva N. Lunetta C. Gerardi F. Cotelli M.S. Rinaldi F. Chiveri L. Guaita M.C. Perrone P. Ceroni M. Diamanti L. Ferrarese C. Tremolizzo L. Delodovici M.L. Bono G. Canosa A. Manera U. Vasta R. Bombaci A. Casale F. Fuda G. Salamone P. Iazzolino B. Peotta L. Cugnasco P. De Marco G. Torrieri M.C. Palumbo F. Gallone S. Barberis M. Sbaiz L. Gentile S. Mauro A. Mazzini L. De Marchi F. Corrado L. D’Alfonso S. Bertolotto A. Gionco M. Leotta D. Odddenino E. Imperiale D. Cavallo R. Pignatta P. De Mattei M. Geda C. Papurello D.M. Gusmaroli G. Comi C. Labate C. Ruiz L. Ferrandi D. Rota E. Aguggia M. Di Vito N. Meineri P. Ghiglione P. Launaro N. Dotta M. Di Sapio A. Giardini G. Tiloca C. Peverelli S. Taroni F. Pensato V. Castellotti B. Comi G.P. Del Bo R. Ceroni M. Gagliardi S. Corrado L. Mazzini L. Raggi F. Simoncini C. Lo Gerfo A. Inghilleri M. Ferlini A. Simone I.L. Passarella B. Guerra V. Zoccolella S. Nozzoli C. Mundi C. Leone M. Zarrelli M. Tamma F. Valluzzi F. Calabrese G. Boero G. Rini A. Traynor B.J. Singleton A.B. Mitne Neto M. Cauchi R.J. Ophoff R.A. Wiedau-Pazos M. Lomen-Hoerth C. van Deerlin V.M. Grosskreutz J. Roediger A. Gaur N. Jörk A. Barthel T. Theele E. Ilse B. Stubendorff B. Witte O.W. Steinbach R. Hübner C.A. Graff C. Brylev L. Fominykh V. Demeshonok V. Ataulina A. Rogelj B. Koritnik B. Zidar J. Ravnik-Glavač M. Glavač D. Stević Z. Drory V. Povedano M. Blair I.P. Kiernan M.C. Benyamin B. Henderson R.D. Furlong S. Mathers S. McCombe P.A. Needham M. Ngo S.T. Nicholson G.A. Pamphlett R. Rowe D.B. Steyn F.J. Williams K.L. Mather K.A. Sachdev P.S. Henders A.K. Wallace L. de Carvalho M. Pinto S. Petri S. Weber M. Rouleau G.A. Silani V. Curtis C.J. Breen G. Glass J.D. Brown R.H. Jr Landers J.E. Shaw C.E. Andersen P.M. Groen E.J.N. van Es M.A. Pasterkamp R.J. Fan D. Garton F.C. McRae A.F. Davey Smith G. Gaunt T.R. Eberle M.A. Mill J. McLaughlin R.L. Hardiman O. Kenna K.P. Wray N.R. Tsai E. Runz H. Franke L. Al-Chalabi A. Van Damme P. van den Berg L.H. Veldink J.H. Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. Nat. Genet. 2021 53 12 1636 1648 10.1038/s41588-021-00973-1 34873335
26 Casas C. Manzano R. Vaz R. Osta R. Brites D. Synaptic failure: Focus in an integrative view of ALS. Brain Plast. 2016 1 2 159 175 10.3233/BPL-140001 29765840
27 Fogarty M. Amyotrophic lateral sclerosis as a synaptopathy. Neural Regen. Res. 2019 14 2 189 192 10.4103/1673-5374.244782 30530995
28 Genç B. Jara J.H. Lagrimas A.K.B. Pytel P. Roos R.P. Mesulam M.M. Geula C. Bigio E.H. Özdinler P.H. Apical dendrite degeneration, a novel cellular pathology for Betz cells in ALS. Sci. Rep. 2017 7 1 41765 10.1038/srep41765 28165465
29 Guidotti G. Scarlata C. Brambilla L. Rossi D. Tumor necrosis factor alpha in amyotrophic lateral sclerosis: Friend or foe? Cells 2021 10 3 518 10.3390/cells10030518 33804386
30 Bursch F. Kalmbach N. Naujock M. Staege S. Eggenschwiler R. Abo-Rady M. Japtok J. Guo W. Hensel N. Reinhardt P. Boeckers T.M. Cantz T. Sterneckert J. Van Den Bosch L. Hermann A. Petri S. Wegner F. Altered calcium dynamics and glutamate receptor properties in iPSC-derived motor neurons from ALS patients with C9orf72, FUS, SOD1 or TDP43 mutations. Hum. Mol. Genet. 2019 28 17 2835 2850 10.1093/hmg/ddz107 31108504
31 Bonifacino T. Provenzano F. Gallia E. Ravera S. Torazza C. Bossi S. Ferrando S. Puliti A. Van Den Bosch L. Bonanno G. Milanese M. In-vivo genetic ablation of metabotropic glutamate receptor type 5 slows down disease progression in the SOD1G93A mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis. 2019 129 79 92 10.1016/j.nbd.2019.05.007 31102766
32 Vermeiren Y. Janssens J. Van Dam D. De Deyn P.P. Serotonergic dysfunction in amyotrophic lateral sclerosis and parkinson’s disease: Similar mechanisms, dissimilar outcomes. Front. Neurosci. 2018 12 185 10.3389/fnins.2018.00185 29615862
33 Yang Y. Gozen O. Watkins A. Lorenzini I. Lepore A. Gao Y. Vidensky S. Brennan J. Poulsen D. Won Park J. Li Jeon N. Robinson M.B. Rothstein J.D. Presynaptic regulation of astroglial excitatory neurotransmitter transporter GLT1. Neuron 2009 61 6 880 894 10.1016/j.neuron.2009.02.010 19323997
34 Scamps F. Aimond F. Hilaire C. Raoul C. Synaptic transmission and motoneuron excitability defects in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis Exon Publications: Brisbane (AU) 2021 10.36255/exonpublications.amyotrophiclateralsclerosis.synaptictransmission.2021
35 Sunico C.R. Domínguez G. García-Verdugo J.M. Osta R. Montero F. Moreno-López B. Reduction in the motoneuron inhibitory/excitatory synaptic ratio in an early-symptomatic mouse model of amyotrophic lateral sclerosis. Brain Pathol. 2011 21 1 1 15 10.1111/j.1750-3639.2010.00417.x 20653686
36 Sirabella R. Valsecchi V. Anzilotti S. Cuomo O. Vinciguerra A. Cepparulo P. Brancaccio P. Guida N. Blondeau N. Canzoniero L.M.T. Franco C. Amoroso S. Annunziato L. Pignataro G. Ionic homeostasis maintenance in ALS: Focus on new therapeutic targets. Front. Neurosci. 2018 12 510 10.3389/fnins.2018.00510 30131665
37 Ragagnin A.M.G. Shadfar S. Vidal M. Jamali M.S. Atkin J.D. Motor neuron susceptibility in ALS/FTD. Front. Neurosci. 2019 13 532 10.3389/fnins.2019.00532 31316328
38 Tateno M. Kato S. Sakurai T. Nukina N. Takahashi R. Araki T. Mutant SOD1 impairs axonal transport of choline acetyltransferase and acetylcholine release by sequestering KAP3. Hum. Mol. Genet. 2009 18 5 942 955 10.1093/hmg/ddn422 19088126
39 Verma S. Khurana S. Vats A. Sahu B. Ganguly N.K. Chakraborti P. Gourie-Devi M. Taneja V. Neuromuscular junction dysfunction in amyotrophic lateral sclerosis. Mol. Neurobiol. 2022 59 3 1502 1527 10.1007/s12035-021-02658-6 34997540
40 Lin C.Y. Wu C.L. Lee K.Z. Chen Y.J. Zhang P.H. Chang C.Y. Harn H.J. Lin S.Z. Tsai H.J. Extracellular Pgk1 enhances neurite outgrowth of motoneurons through Nogo66/NgR-independent targeting of NogoA. eLife 2019 8 e49175 10.7554/eLife.49175 31361595
41 Venkova K. Christov A. Kamaluddin Z. Kobalka P. Siddiqui S. Hensley K. Semaphorin 3A signaling through neuropilin-1 is an early trigger for distal axonopathy in the SOD1G93A mouse model of amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 2014 73 7 702 713 10.1097/NEN.0000000000000086 24918638
42 Moloney E.B. de Winter F. Verhaagen J. ALS as a distal axonopathy: Molecular mechanisms affecting neuromuscular junction stability in the presymptomatic stages of the disease. Front. Neurosci. 2014 8 252 10.3389/fnins.2014.00252 25177267
43 Krieger C. Wang S.J.H. Yoo S.H. Harden N. Adducin at the neuromuscular junction in amyotrophic lateral sclerosis: Hanging on for dear life. Front. Cell. Neurosci. 2016 10 11 10.3389/fncel.2016.00011 26858605
44 Palma E. Reyes-Ruiz J.M. Lopergolo D. Roseti C. Bertollini C. Ruffolo G. Cifelli P. Onesti E. Limatola C. Miledi R. Inghilleri M. Acetylcholine receptors from human muscle as pharmacological targets for ALS therapy. Proc. Natl. Acad. Sci. USA 2016 113 11 3060 3065 10.1073/pnas.1600251113 26929355
45 Van Hoecke A. Schoonaert L. Lemmens R. Timmers M. Staats K.A. Laird A.S. Peeters E. Philips T. Goris A. Dubois B. Andersen P.M. Al-Chalabi A. Thijs V. Turnley A.M. van Vught P.W. Veldink J.H. Hardiman O. Van Den Bosch L. Gonzalez-Perez P. Van Damme P. Brown R.H. Jr van den Berg L.H. Robberecht W. EPHA4 is a disease modifier of amyotrophic lateral sclerosis in animal models and in humans. Nat. Med. 2012 18 9 1418 1422 10.1038/nm.2901 22922411
46 Murray L.M. Talbot K. Gillingwater T.H. Review: Neuromuscular synaptic vulnerability in motor neurone disease: amyotrophic lateral sclerosis and spinal muscular atrophy. Neuropathol. Appl. Neurobiol. 2010 36 2 133 156 10.1111/j.1365-2990.2010.01061.x 20202121
47 Schomburg E.D. Steffens H. Zschüntzsch J. Dibaj P. Keller B.U. Fatigability of spinal reflex transmission in a mouse model (SOD1G93A ) of amyotrophic lateral sclerosis. Muscle Nerve 2011 43 2 230 236 10.1002/mus.21835 21254088
48 Rocha M.C. Pousinha P.A. Correia A.M. Sebastião A.M. Ribeiro J.A. Early changes of neuromuscular transmission in the (SOD1G93A ) mice model of ALS start long before motor symptoms onset. PLoS One 2013 8 9 e73846 10.1371/journal.pone.0073846 24040091
49 Carrasco D.I. Seburn K.L. Pinter M.J. Altered terminal Schwann cell morphology precedes denervation in SOD1 mice. Exp. Neurol. 2016 275 0 1 172 181 10.1016/j.expneurol.2015.09.014 26416261
50 Manzano R. Toivonen J.M. Calvo A.C. Oliván S. Zaragoza P. Rodellar C. Montarras D. Osta R. Altered in vitro proliferation of mouse SOD1-G93A skeletal muscle satellite cells. Neurodegener. Dis. 2013 11 3 153 164 10.1159/000338061 22797053
51 Nijssen J. Comley L.H. Hedlund E. Motor neuron vulnerability and resistance in amyotrophic lateral sclerosis. Acta Neuropathol. 2017 133 6 863 885 10.1007/s00401-017-1708-8 28409282
52 Rochat C. Schneider B.L. Bernard-Marissal N. Selective vulnerability of neuronal subtypes in ALS: A fertile ground for the identification of therapeutic targets. Update on Amyotrophic Lateral Sclerosis. InTech 2016 10.5772/63703
53 Ruegsegger C. Maharjan N. Goswami A. Filézac de L’Etang A. Weis J. Troost D. Heller M. Gut H. Saxena S. Aberrant association of misfolded SOD1 with Na+/K+ATPase-α3 impairs its activity and contributes to motor neuron vulnerability in ALS. Acta Neuropathol. 2016 131 3 427 451 10.1007/s00401-015-1510-4 26619836
54 Ramírez-Jarquín U.N. Tapia R. Excitatory and inhibitory neuronal circuits in the spinal cord and their role in the control of motor neuron function and degeneration. ACS Chem. Neurosci. 2018 9 2 211 216 10.1021/acschemneuro.7b00503 29350907
55 Orr B.O. Hauswirth A.G. Celona B. Fetter R.D. Zunino G. Kvon E.Z. Zhu Y. Pennacchio L.A. Black B.L. Davis G.W. Presynaptic homeostasis opposes disease progression in mouse models of ALS-Like degeneration: Evidence for homeostatic neuroprotection. Neuron 2020 107 1 95 111.e6 10.1016/j.neuron.2020.04.009 32380032
56 Wijesekera L.C. Nigel Leigh P. Amyotrophic lateral sclerosis. Orphanet J. Rare Dis. 2009 4 1 3 10.1186/1750-1172-4-3 19192301
57 Isaacs J.D. Dean A.F. Shaw C.E. Al-Chalabi A. Mills K.R. Leigh P.N. Amyotrophic lateral sclerosis with sensory neuropathy: Part of a multisystem disorder? J. Neurol. Neurosurg. Psychiatry 2006 78 7 750 753 10.1136/jnnp.2006.098798 17575021
58 Seki S. Yamamoto T. Quinn K. Spigelman I. Pantazis A. Olcese R. Wiedau-Pazos M. Chandler S.H. Venugopal S. Circuit-specific early impairment of proprioceptive sensory neurons in the SOD1G93A mouse model for ALS. J. Neurosci. 2019 39 44 8798 8815 10.1523/JNEUROSCI.1214-19.2019 31530644
59 Vaughan S.K. Sutherland N.M. Zhang S. Hatzipetros T. Vieira F. Valdez G. The ALS-inducing factors, TDP43A315T and SOD1G93A , directly affect and sensitize sensory neurons to stress. Sci. Rep. 2018 8 1 16582 10.1038/s41598-018-34510-8 30410094
60 Lalancette-Hebert M. Sharma A. Lyashchenko A.K. Shneider N.A. Gamma motor neurons survive and exacerbate alpha motor neuron degeneration in ALS. Proc. Natl. Acad. Sci. USA 2016 113 51 E8316 E8325 10.1073/pnas.1605210113 27930290
61 Brownstone R.M. Lancelin C. Escape from homeostasis: spinal microcircuits and progression of amyotrophic lateral sclerosis. J. Neurophysiol. 2018 119 5 1782 1794 10.1152/jn.00331.2017 29384454
62 Ashford B.A. Boche D. Cooper-Knock J. Heath P.R. Simpson J.E. Highley J.R. Review: Microglia in motor neuron disease. Neuropathol. Appl. Neurobiol. 2021 47 2 179 197 10.1111/nan.12640 32594542
63 Gomes C. Sequeira C. Barbosa M. Cunha C. Vaz A.R. Brites D. Astrocyte regional diversity in ALS includes distinct aberrant phenotypes with common and causal pathological processes. Exp. Cell Res. 2020 395 2 112209 10.1016/j.yexcr.2020.112209 32739211
64 Geloso M.C. Corvino V. Marchese E. Serrano A. Michetti F. D’Ambrosi N. The dual role of microglia in ALS: Mechanisms and therapeutic approaches. Front. Aging Neurosci. 2017 9 242 10.3389/fnagi.2017.00242 28790913
65 Trolese M.C. Mariani A. Terao M. de Paola M. Fabbrizio P. Sironi F. Kurosaki M. Bonanno S. Marcuzzo S. Bernasconi P. Trojsi F. Aronica E. Bendotti C. Nardo G. CXCL13/] CXCR5 signalling is pivotal to preserve motor neurons in amyotrophic lateral sclerosis. EBioMedicine 2020 62 103097 10.1016/j.ebiom.2020.103097 33161233
66 Hensley K. Mhatre M. Mou S. Pye Q.N. Stewart C. West M. Williamson K.S. On the relation of oxidative stress to neuroinflammation: Lessons learned from the G93A-SOD1 mouse model of amyotrophic lateral sclerosis. Antioxid. Redox Signal. 2006 8 11-12 2075 2087 10.1089/ars.2006.8.2075 17034351
67 Puentes F. Malaspina A. van Noort J.M. Amor S. Non-neuronal cells in ALS: Role of glial, immune cells and blood-CNS barriers. Brain Pathol. 2016 26 2 248 257 10.1111/bpa.12352 26780491
68 Santoni G. Cardinali C. Morelli M. Santoni M. Nabissi M. Amantini C. Danger- and pathogen-associated molecular patterns recognition by pattern-recognition receptors and ion channels of the transient receptor potential family triggers the inflammasome activation in immune cells and sensory neurons. J. Neuroinflammation 2015 12 1 21 10.1186/s12974-015-0239-2 25644504
69 Ouali A.N. Schurr C. Olde Heuvel F. Tang L. Li Q. Tasdogan A. Kimbara A. Nettekoven M. Ottaviani G. Raposo C. Röver S. Rogers-Evans M. Rothenhäusler B. Ullmer C. Fingerle J. Grether U. Knuesel I. Boeckers T.M. Ludolph A. Wirth T. Roselli F. Baumann B. NF‐κB activation in astrocytes drives a stage‐specific beneficial neuroimmunological response in ALS. EMBO J. 2018 37 16 e98697 10.15252/embj.201798697 29875132
70 Liddelow S.A. Guttenplan K.A. Clarke L.E. Bennett F.C. Bohlen C.J. Schirmer L. Bennett M.L. Münch A.E. Chung W.S. Peterson T.C. Wilton D.K. Frouin A. Napier B.A. Panicker N. Kumar M. Buckwalter M.S. Rowitch D.H. Dawson V.L. Dawson T.M. Stevens B. Barres B.A. Neurotoxic reactive astrocytes are induced by activated microglia. Nature 2017 541 7638 481 487 10.1038/nature21029 28099414
71 Vaz S.H. Pinto S. Sebastião A.M. Brites D. Astrocytes in amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Araki T. Brisbane Exon Publications 2021 10.36255/exonpublications.amyotrophiclateralsclerosis.astrocytes.2021
72 Zhao W. Beers D.R. Appel S.H. Immune-mediated mechanisms in the pathoprogression of amyotrophic lateral sclerosis. J. Neuroimmune Pharmacol. 2013 8 4 888 899 10.1007/s11481-013-9489-x 23881705
73 Johann S. Heitzer M. Kanagaratnam M. Goswami A. Rizo T. Weis J. Troost D. Beyer C. NLRP3 inflammasome is expressed by astrocytes in the SOD1 mouse model of ALS and in human sporadic ALS patients. Glia 2015 63 12 2260 2273 10.1002/glia.22891 26200799
74 MacLean M. Juranek J. Cuddapah S. López-Díez R. Ruiz H.H. Hu J. Frye L. Li H. Gugger P.F. Schmidt A.M. Microglia RAGE exacerbates the progression of neurodegeneration within the SOD1G93A murine model of amyotrophic lateral sclerosis in a sex-dependent manner. J. Neuroinflammation 2021 18 1 139 10.1186/s12974-021-02191-2 34130712
75 Eitan C. Siany A. Barkan E. Olender T. van Eijk K.R. Moisse M. Farhan S.M.K. Danino Y.M. Yanowski E. Marmor-Kollet H. Rivkin N. Yacovzada N.S. Hung S.T. Cooper-Knock J. Yu C.H. Louis C. Masters S.L. Kenna K.P. van der Spek R.A.A. Sproviero W. Al Khleifat A. Iacoangeli A. Shatunov A. Jones A.R. Elbaz-Alon Y. Cohen Y. Chapnik E. Rothschild D. Weissbrod O. Beck G. Ainbinder E. Ben-Dor S. Werneburg S. Schafer D.P. Brown R.H. Jr Shaw P.J. Van Damme P. van den Berg L.H. Phatnani H. Segal E. Ichida J.K. Al-Chalabi A. Veldink J.H. Cooper-Knock J. Kenna K.P. Van Damme P. van den Berg L.H. Hornstein E. Hornstein E. Whole-genome sequencing reveals that variants in the Interleukin 18 Receptor Accessory Protein 3′UTR protect against ALS. Nat. Neurosci. 2022 25 4 433 445 10.1038/s41593-022-01040-6 35361972
76 Beers D.R. Henkel J.S. Zhao W. Wang J. Appel S.H. CD4+ T cells support glial neuroprotection, slow disease progression, and modify glial morphology in an animal model of inherited ALS. Proc. Natl. Acad. Sci. USA 2008 105 40 15558 15563 10.1073/pnas.0807419105 18809917
77 Henkel J.S. Beers D.R. Wen S. Rivera A.L. Toennis K.M. Appel J.E. Zhao W. Moore D.H. Powell S.Z. Appel S.H. Regulatory T‐lymphocytes mediate amyotrophic lateral sclerosis progression and survival. EMBO Mol. Med. 2013 5 1 64 79 10.1002/emmm.201201544 23143995
78 McCombe P.A. Lee J.D. Woodruff T.M. Henderson R.D. The peripheral immune system and amyotrophic lateral sclerosis. Front. Neurol. 2020 11 279 10.3389/fneur.2020.00279 32373052
79 Volonté C. Apolloni S. Parisi C. Amadio S. Purinergic contribution to amyotrophic lateral sclerosis. Neuropharmacology 2016 104 180 193 10.1016/j.neuropharm.2015.10.026 26514402
80 Sta M. Sylva-Steenland R.M.R. Casula M. de Jong J.M.B.V. Troost D. Aronica E. Baas F. Innate and adaptive immunity in amyotrophic lateral sclerosis: Evidence of complement activation. Neurobiol. Dis. 2011 42 3 211 220 10.1016/j.nbd.2011.01.002 21220013
81 Kakaroubas N. Brennan S. Keon M. Saksena N.K. Pathomechanisms of blood-brain barrier disruption in ALS. Neurosci. J. 2019 2019 1 16 10.1155/2019/2537698 31380411
82 Saul J. Hutchins E. Reiman R. Saul M. Ostrow L.W. Harris B.T. Van Keuren-Jensen K. Bowser R. Bakkar N. Global alterations to the choroid plexus blood-CSF barrier in amyotrophic lateral sclerosis. Acta Neuropathol. Commun. 2020 8 1 92 10.1186/s40478-020-00968-9 32586411
83 Bowerman M. The neuroinflammation in the physiopathology of amyotrophic lateral sclerosis. Curr. Adv. Amyotrophic Lateral Sclerosis InTech 2013 10.5772/56489
84 Jiang L.L. Zhu B. Zhao Y. Li X. Liu T. Pina-Crespo J. Zhou L. Xu W. Rodriguez M.J. Yu H. Cleveland D.W. Ravits J. Da Cruz S. Long T. Zhang D. Huang T.Y. Xu H. Membralin deficiency dysregulates astrocytic glutamate homeostasis, leading to ALS-like impairment. J. Clin. Invest. 2019 129 8 3103 3120 10.1172/JCI127695 31112137
85 Yin X. Wang S. Qi Y. Wang X. Jiang H. Wang T. Yang Y. Wang Y. Zhang C. Feng H. Astrocyte elevated gene-1 is a novel regulator of astrogliosis and excitatory amino acid transporter-2 via interplaying with nuclear factor-κB signaling in astrocytes from amyotrophic lateral sclerosis mouse model with hSOD1 G93A mutation. Mol. Cell. Neurosci. 2018 90 1 11 10.1016/j.mcn.2018.05.004 29777762
86 Rosenblum L.T. Shamamandri-Markandaiah S. Ghosh B. Foran E. Lepore A.C. Pasinelli P. Trotti D. Mutation of the caspase-3 cleavage site in the astroglial glutamate transporter EAAT2 delays disease progression and extends lifespan in the SOD1-G93A mouse model of ALS. Exp. Neurol. 2017 292 145 153 10.1016/j.expneurol.2017.03.014 28342750
87 Chen L.C. Smith A.P. Ben Y. Zukic B. Ignacio S. Moore D. Lee N.M. Temporal gene expression patterns in G93A/SOD1 mouse. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 2004 5 3 164 171 10.1080/14660820410017091 15512905
88 Lopez-Lopez A. Gamez J. Syriani E. Morales M. Salvado M. Rodríguez M.J. Mahy N. Vidal-Taboada J.M. CX3CR1 is a modifying gene of survival and progression in amyotrophic lateral sclerosis. PLoS One 2014 9 5 e96528 10.1371/journal.pone.0096528 24806473
89 Tripathi P. Rodriguez-Muela N. Klim J.R. de Boer A.S. Agrawal S. Sandoe J. Lopes C.S. Ogliari K.S. Williams L.A. Shear M. Rubin L.L. Eggan K. Zhou Q. Reactive astrocytes promote ALS-like degeneration and intracellular protein aggregation in human motor neurons by disrupting autophagy through TGF-β1. Stem Cell Reports 2017 9 2 667 680 10.1016/j.stemcr.2017.06.008 28712846
90 Cassina P. Miquel E. Martínez-Palma L. Cassina A. Glial metabolic reprogramming in amyotrophic lateral sclerosis. Neuroimmunomodulation 2021 28 4 204 212 10.1159/000516926 34175843
91 Moisse K. Strong M.J. Innate immunity in amyotrophic lateral sclerosis. Biochim. Biophys. Acta Mol. Basis Dis. 2006 1762 11-12 1083 1093 10.1016/j.bbadis.2006.03.001 16624536
92 Raffaele S. Boccazzi M. Fumagalli M. Oligodendrocyte dysfunction in amyotrophic lateral sclerosis: Mechanisms and therapeutic perspectives. Cells 2021 10 3 565 10.3390/cells10030565 33807572
93 Ito Y. Ofengeim D. Najafov A. Das S. Saberi S. Li Y. Hitomi J. Zhu H. Chen H. Mayo L. Geng J. Amin P. DeWitt J.P. Mookhtiar A.K. Florez M. Ouchida A.T. Fan J. Pasparakis M. Kelliher M.A. Ravits J. Yuan J. RIPK1 mediates axonal degeneration by promoting inflammation and necroptosis in ALS. Science 2016 353 6299 603 608 10.1126/science.aaf6803 27493188
94 Liu J.F. Zheng O.X. Xin J.G. Chen H.H. Xin J.J. How are necroptosis, immune dysfunction, and motoneuron death connected in amyotrophic lateral sclerosis? Neuroimmunol. Neuroinflamm. 2017 4 6 109 116 10.20517/2347-8659.2017.12
95 Endo F. Komine O. Yamanaka K. Neuroinflammation in motor neuron disease. Clin. Exp. Neuroimmunol. 2016 7 2 126 138 10.1111/cen3.12309
96 Trias E. King P.H. Si Y. Kwon Y. Varela V. Ibarburu S. Kovacs M. Moura I.C. Beckman J.S. Hermine O. Barbeito L. Mast cells and neutrophils mediate peripheral motor pathway degeneration in ALS. JCI Insight 2018 3 19 e123249 10.1172/jci.insight.123249 30282815
97 Kang S.H. Li Y. Fukaya M. Lorenzini I. Cleveland D.W. Ostrow L.W. Rothstein J.D. Bergles D.E. Degeneration and impaired regeneration of gray matter oligodendrocytes in amyotrophic lateral sclerosis. Nat. Neurosci. 2013 16 5 571 579 10.1038/nn.3357 23542689
98 Filipi T. Hermanova Z. Tureckova J. Vanatko O. Anderova M. Glial cells—the strategic targets in amyotrophic lateral sclerosis treatment. J. Clin. Med. 2020 9 1 261 10.3390/jcm9010261 31963681
99 Mishra P.S. Boutej H. Soucy G. Bareil C. Kumar S. Picher-Martel V. Dupré N. Kriz J. Julien J.P. Transmission of ALS pathogenesis by the cerebrospinal fluid. Acta Neuropathol. Commun. 2020 8 1 65 10.1186/s40478-020-00943-4 32381112
100 Sumitha R. Manjunatha V.M. Sabitha R.K. Alladi P.A. Nalini A. Rao L.T. Chandrasekhar Sagar B.K. Steinbusch H.W.M. Kramer B.W. Sathyaprabha T.N. Raju T.R. Cerebrospinal fluid from patients with sporadic amyotrophic lateral sclerosis induces degeneration of motor neurons derived from human embryonic stem cells. Mol. Neurobiol. 2019 56 2 1014 1034 10.1007/s12035-018-1149-y 29858777
101 Mishra P.S. Vijayalakshmi K. Nalini A. Sathyaprabha T.N. Kramer B.W. Alladi P.A. Raju T.R. Etiogenic factors present in the cerebrospinal fluid from amyotrophic lateral sclerosis patients induce predominantly pro-inflammatory responses in microglia. J. Neuroinflammation 2017 14 1 251 10.1186/s12974-017-1028-x 29246232
102 Clement A.M. Nguyen M.D. Roberts E.A. Garcia M.L. Boillée S. Rule M. McMahon A.P. Doucette W. Siwek D. Ferrante R.J. Brown R.H. Jr Julien J.P. Goldstein L.S.B. Cleveland D.W. Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science 2003 302 5642 113 117 10.1126/science.1086071 14526083
103 Lobsiger C.S. Boillee S. McAlonis-Downes M. Khan A.M. Feltri M.L. Yamanaka K. Cleveland D.W. Schwann cells expressing dismutase active mutant SOD1 unexpectedly slow disease progression in ALS mice. Proc. Natl. Acad. Sci. USA 2009 106 11 4465 4470 10.1073/pnas.0813339106 19251638
104 Boillée S. Yamanaka K. Lobsiger C.S. Copeland N.G. Jenkins N.A. Kassiotis G. Kollias G. Cleveland D.W. Onset and progression in inherited ALS determined by motor neurons and microglia. Science 2006 312 5778 1389 1392 10.1126/science.1123511 16741123
105 Van Harten A.C.M. Phatnani H. Przedborski S. Non-cell-autonomous pathogenic mechanisms in amyotrophic lateral sclerosis. Trends Neurosci. 2021 44 8 658 668 10.1016/j.tins.2021.04.008 34006386
106 Damme M. Suntio T. Saftig P. Eskelinen E.L. Autophagy in neuronal cells: general principles and physiological and pathological functions. Acta Neuropathol. 2015 129 3 337 362 10.1007/s00401-014-1361-4 25367385
107 Sasaki S. Autophagy in spinal cord motor neurons in sporadic amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 2011 70 5 349 359 10.1097/NEN.0b013e3182160690 21487309
108 Fernando R. Castro J.P. Flore T. Deubel S. Grune T. Ott C. Age-related maintenance of the autophagy-lysosomal system is dependent on skeletal muscle type. Oxid. Med. Cell. Longev. 2020 2020 1 8 10.1155/2020/4908162 32774673
109 Amin A. Perera N.D. Beart P.M. Turner B.J. Shabanpoor F. Amyotrophic lateral sclerosis and autophagy: Dysfunction and therapeutic targeting. Cells 2020 9 11 2413 10.3390/cells9112413 33158177
110 Fujikake N. Shin M. Shimizu S. Association between autophagy and neurodegenerative diseases. Front. Neurosci. 2018 12 255 10.3389/fnins.2018.00255 29872373
111 Chen A.I. Xiong L.J. Tong Y.U. Mao M. Neuroprotective effect of brain-derived neurotrophic factor mediated by autophagy through the PI3K/Akt/mTOR pathway. Mol. Med. Rep. 2013 8 4 1011 1016 10.3892/mmr.2013.1628 23942837
112 Ugolino J. Ji Y.J. Conchina K. Chu J. Nirujogi R.S. Pandey A. Brady N.R. Hamacher-Brady A. Wang J. Loss of C9orf72 enhances autophagic activity via deregulated mTOR and TFEB signaling. PLoS Genet. 2016 12 11 e1006443 e1006443 10.1371/journal.pgen.1006443 27875531
113 Budini M. Buratti E. Morselli E. Criollo A. Autophagy and its impact on neurodegenerative diseases: New roles for TDP-43 and C9orf72. Front. Mol. Neurosci. 2017 10 170 10.3389/fnmol.2017.00170 28611593
114 Chew J. Cook C. Gendron T.F. Jansen-West K. del Rosso G. Daughrity L.M. Castanedes-Casey M. Kurti A. Stankowski J.N. Disney M.D. Rothstein J.D. Dickson D.W. Fryer J.D. Zhang Y.J. Petrucelli L. Aberrant deposition of stress granule-resident proteins linked to C9orf72-associated TDP-43 proteinopathy. Mol. Neurodegener. 2019 14 1 9 10.1186/s13024-019-0310-z 30767771
115 Nguyen D.K.H. Thombre R. Wang J. Autophagy as a common pathway in amyotrophic lateral sclerosis. Neurosci. Lett. 2019 697 34 48 10.1016/j.neulet.2018.04.006 29626651
116 Oakes J.A. Davies M.C. Collins M.O. TBK1: a new player in ALS linking autophagy and neuroinflammation. Mol. Brain 2017 10 1 5 10.1186/s13041-017-0287-x 28148298
117 Tak Y.J. Park J.H. Rhim H. Kang S. ALS-related mutant SOD1 aggregates interfere with mitophagy by sequestering the autophagy receptor optineurin. Int. J. Mol. Sci. 2020 21 20 7525 10.3390/ijms21207525 33065963
118 Zhang Y.J. Jansen-West K. Xu Y.F. Gendron T.F. Bieniek K.F. Lin W.L. Sasaguri H. Caulfield T. Hubbard J. Daughrity L. Chew J. Belzil V.V. Prudencio M. Stankowski J.N. Castanedes-Casey M. Whitelaw E. Ash P.E.A. DeTure M. Rademakers R. Boylan K.B. Dickson D.W. Petrucelli L. Aggregation-prone c9FTD/ALS poly(GA) RAN-translated proteins cause neurotoxicity by inducing ER stress. Acta Neuropathol. 2014 128 4 505 524 10.1007/s00401-014-1336-5 25173361
119 Soo K.Y. Sultana J. King A.E. Atkinson R.A.K. Warraich S.T. Sundaramoorthy V. Blair I. Farg M.A. Atkin J.D. ALS-associated mutant FUS inhibits macroautophagy which is restored by overexpression of Rab1. Cell Death Discov. 2015 1 1 15030 10.1038/cddiscovery.2015.30 27551461
120 Purice M.D. Taylor J.P. Linking hnRNP function to ALS and FTD pathology. Front. Neurosci. 2018 12 326 10.3389/fnins.2018.00326 29867335
121 Renaud L. Picher-Martel V. Codron P. Julien J.P. Key role of UBQLN2 in pathogenesis of amyotrophic lateral sclerosis and frontotemporal dementia. Acta Neuropathol. Commun. 2019 7 1 103 10.1186/s40478-019-0758-7 31319884
122 Burk K. Pasterkamp R.J. Disrupted neuronal trafficking in amyotrophic lateral sclerosis. Acta Neuropathol. 2019 137 6 859 877 10.1007/s00401-019-01964-7 30721407
123 Theunissen F. West P.K. Brennan S. Petrović B. Hooshmand K. Akkari P.A. Keon M. Guennewig B. New perspectives on cytoskeletal dysregulation and mitochondrial mislocalization in amyotrophic lateral sclerosis. Transl. Neurodegener. 2021 10 1 46 10.1186/s40035-021-00272-z 34789332
124 Kieran D. Hafezparast M. Bohnert S. Dick J.R.T. Martin J. Schiavo G. Fisher E.M.C. Greensmith L. A mutation in dynein rescues axonal transport defects and extends the life span of ALS mice. J. Cell Biol. 2005 169 4 561 567 10.1083/jcb.200501085 15911875
125 Shi Y. Lin S. Staats K.A. Li Y. Chang W.H. Hung S.T. Hendricks E. Linares G.R. Wang Y. Son E.Y. Wen X. Kisler K. Wilkinson B. Menendez L. Sugawara T. Woolwine P. Huang M. Cowan M.J. Ge B. Koutsodendris N. Sandor K.P. Komberg J. Vangoor V.R. Senthilkumar K. Hennes V. Seah C. Nelson A.R. Cheng T.Y. Lee S.J.J. August P.R. Chen J.A. Wisniewski N. Hanson-Smith V. Belgard T.G. Zhang A. Coba M. Grunseich C. Ward M.E. van den Berg L.H. Pasterkamp R.J. Trotti D. Zlokovic B.V. Ichida J.K. Haploinsufficiency leads to neurodegeneration in C9ORF72 ALS/FTD human induced motor neurons. Nat. Med. 2018 24 3 313 325 10.1038/nm.4490 29400714
126 Slowicka K. Vereecke L. van Loo G. Cellular functions of optineurin in health and disease. Trends Immunol. 2016 37 9 621 633 10.1016/j.it.2016.07.002 27480243
127 Rademakers R. van Blitterswijk M. Excess of rare damaging TUBA4A variants suggests cytoskeletal defects in ALS. Neuron 2014 84 2 241 243 10.1016/j.neuron.2014.10.002 25374348
128 Laird F.M. Farah M.H. Ackerley S. Hoke A. Maragakis N. Rothstein J.D. Griffin J. Price D.L. Martin L.J. Wong P.C. Motor neuron disease occurring in a mutant dynactin mouse model is characterized by defects in vesicular trafficking. J. Neurosci. 2008 28 9 1997 2005 10.1523/JNEUROSCI.4231-07.2008 18305234
129 Nicolas A. Kenna K.P. Renton A.E. Ticozzi N. Faghri F. Chia R. Dominov J.A. Kenna B.J. Nalls M.A. Keagle P. Rivera A.M. van Rheenen W. Murphy N.A. van Vugt J.J.F.A. Geiger J.T. Van der Spek R.A. Pliner H.A. Shankaracharya; Smith, B.N.; Marangi, G.; Topp, S.D.; Abramzon, Y.; Gkazi, A.S.; Eicher, J.D.; Kenna, A.; Mora, G.; Calvo, A.; Mazzini, L.; Riva, N.; Mandrioli, J.; Caponnetto, C.; Battistini, S.; Volanti, P.; La Bella, V.; Conforti, F.L.; Borghero, G.; Messina, S.; Simone, I.L.; Trojsi, F.; Salvi, F.; Logullo, F.O.; D’Alfonso, S.; Corrado, L.; Capasso, M.; Ferrucci, L.; Moreno, C.A.M.; Kamalakaran, S.; Goldstein, D.B.; Gitler, A.D.; Harris, T.; Myers, R.M.; Phatnani, H.; Musunuri, R.L.; Evani, U.S.; Abhyankar, A.; Zody, M.C.; Kaye, J.; Finkbeiner, S.; Wyman, S.K.; LeNail, A.; Lima, L.; Fraenkel, E.; Svendsen, C.N.; Thompson, L.M.; Van Eyk, J.E.; Berry, J.D.; Miller, T.M.; Kolb, S.J.; Cudkowicz, M.; Baxi, E.; Benatar, M.; Taylor, J.P.; Rampersaud, E.; Wu, G.; Wuu, J.; Lauria, G.; Verde, F.; Fogh, I.; Tiloca, C.; Comi, G.P.; Sorarù, G.; Cereda, C.; Corcia, P.; Laaksovirta, H.; Myllykangas, L.; Jansson, L.; Valori, M.; Ealing, J.; Hamdalla, H.; Rollinson, S.; Pickering-Brown, S.; Orrell, R.W.; Sidle, K.C.; Malaspina, A.; Hardy, J.; Singleton, A.B.; Johnson, J.O.; Arepalli, S.; Sapp, P.C.; McKenna-Yasek, D.; Polak, M.; Asress, S.; Al-Sarraj, S.; King, A.; Troakes, C.; Vance, C.; de Belleroche, J.; Baas, F.; ten Asbroek, A.L.M.A.; Muñoz-Blanco, J.L.; Hernandez, D.G.; Ding, J.; Gibbs, J.R.; Scholz, S.W.; Floeter, M.K.; Campbell, R.H.; Landi, F.; Bowser, R.; Pulst, S.M.; Ravits, J.M.; MacGowan, D.J.L.; Kirby, J.; Pioro, E.P.; Pamphlett, R.; Broach, J.; Gerhard, G.; Dunckley, T.L.; Brady, C.B.; Kowall, N.W.; Troncoso, J.C.; Le Ber, I.; Mouzat, K.; Lumbroso, S.; Heiman-Patterson, T.D.; Kamel, F.; Van Den Bosch, L.; Baloh, R.H.; Strom, T.M.; Meitinger, T.; Shatunov, A.; Van Eijk, K.R.; de Carvalho, M.; Kooyman, M.; Middelkoop, B.; Moisse, M.; McLaughlin, R.L.; Van Es, M.A.; Weber, M.; Boylan, K.B.; Van Blitterswijk, M.; Rademakers, R.; Morrison, K.E.; Basak, A.N.; Mora, J.S.; Drory, V.E.; Shaw, P.J.; Turner, M.R.; Talbot, K.; Hardiman, O.; Williams, K.L.; Fifita, J.A.; Nicholson, G.A.; Blair, I.P.; Rouleau, G.A.; Esteban-Pérez, J.; García-Redondo, A.; Al-Chalabi, A.; Rogaeva, E.; Zinman, L.; Ostrow, L.W.; Maragakis, N.J.; Rothstein, J.D.; Simmons, Z.; Cooper-Knock, J.; Brice, A.; Goutman, S.A.; Feldman, E.L.; Gibson, S.B.; Taroni, F.; Ratti, A.; Gellera, C.; Van Damme, P.; Robberecht, W.; Fratta, P.; Sabatelli, M.; Lunetta, C.; Ludolph, A.C.; Andersen, P.M.; Weishaupt, J.H.; Camu, W.; Trojanowski, J.Q.; Van Deerlin, V.M.; Brown, R.H., Jr; van den Berg, L.H.; Veldink, J.H.; Harms, M.B.; Glass, J.D.; Stone, D.J.; Tienari, P.; Silani, V.; Chiò, A.; Shaw, C.E.; Traynor, B.J.; Landers, J.E.; Logullo, F.O.; Simone, I.; Logroscino, G.; Salvi, F.; Bartolomei, I.; Borghero, G.; Murru, M.R.; Costantino, E.; Pani, C.; Puddu, R.; Caredda, C.; Piras, V.; Tranquilli, S.; Cuccu, S.; Corongiu, D.; Melis, M.; Milia, A.; Marrosu, F.; Marrosu, M.G.; Floris, G.; Cannas, A.; Tranquilli, S.; Capasso, M.; Caponnetto, C.; Mancardi, G.; Origone, P.; Mandich, P.; Conforti, F.L.; Cavallaro, S.; Mora, G.; Marinou, K.; Sideri, R.; Penco, S.; Mosca, L.; Lunetta, C.; Pinter, G.L.; Corbo, M.; Riva, N.; Carrera, P.; Volanti, P.; Mandrioli, J.; Fini, N.; Fasano, A.; Tremolizzo, L.; Arosio, A.; Ferrarese, C.; Trojsi, F.; Tedeschi, G.; Monsurrò, M.R.; Piccirillo, G.; Femiano, C.; Ticca, A.; Ortu, E.; La Bella, V.; Spataro, R.; Colletti, T.; Sabatelli, M.; Zollino, M.; Conte, A.; Luigetti, M.; Lattante, S.; Marangi, G.; Santarelli, M.; Petrucci, A.; Pugliatti, M.; Pirisi, A.; Parish, L.D.; Occhineri, P.; Giannini, F.; Battistini, S.; Ricci, C.; Benigni, M.; Cau, T.B.; Loi, D.; Calvo, A.; Moglia, C.; Brunetti, M.; Barberis, M.; Restagno, G.; Casale, F.; Marrali, G.; Fuda, G.; Ossola, I.; Cammarosano, S.; Canosa, A.; Ilardi, A.; Manera, U.; Grassano, M.; Tanel, R.; Pisano, F.; Harms, M.B.; Goldstein, D.B.; Shneider, N.A.; Goutman, S.; Simmons, Z.; Miller, T.M.; Chandran, S.; Pal, S.; Manousakis, G.; Appel, S.H.; Simpson, E.; Wang, L.; Baloh, R.H.; Gibson, S.; Bedlack, R.; Lacomis, D.; Sareen, D.; Sherman, A.; Bruijn, L.; Penny, M.; Allen, A.S.; Appel, S.; Baloh, R.H.; Bedlack, R.S.; Boone, B.E.; Brown, R.; Carulli, J.P.; Chesi, A.; Chung, W.K.; Cirulli, E.T.; Cooper, G.M.; Couthouis, J.; Day-Williams, A.G.; Dion, P.A.; Gibson, S.; Gitler, A.D.; Glass, J.D.; Goldstein, D.B.; Han, Y.; Harms, M.B.; Harris, T.; Hayes, S.D.; Jones, A.L.; Keebler, J.; Krueger, B.J.; Lasseigne, B.N.; Levy, S.E.; Lu, Y-F.; Maniatis, T.; McKenna-Yasek, D.; Miller, T.M.; Myers, R.M.; Petrovski, S.; Pulst, S.M.; Raphael, A.R.; Ravits, J.M.; Ren, Z.; Rouleau, G.A.; Sapp, P.C.; Shneider, N.A.; Simpson, E.; Sims, K.B.; Staropoli, J.F.; Waite, L.L.; Wang, Q.; Wimbish, J.R.; Xin, W.W.; Phatnani, H.; Kwan, J.; Sareen, D.; Broach, J.R.; Simmons, Z.; Arcila-Londono, X.; Lee, E.B.; Van Deerlin, V.M.; Shneider, N.A.; Fraenkel, E.; Ostrow, L.W.; Baas, F.; Zaitlen, N.; Berry, J.D.; Malaspina, A.; Fratta, P.; Cox, G.A.; Thompson, L.M.; Finkbeiner, S.; Dardiotis, E.; Miller, T.M.; Chandran, S.; Pal, S.; Hornstein, E.; MacGowan, D.J.; Heiman-Patterson, T.; Hammell, M.G.; Patsopoulos, N.A.; Dubnau, J.; Nath, A.; Kaye, J.; Finkbeiner, S.; Wyman, S.; LeNail, A.; Lima, L.; Fraenkel, E.; Rothstein, J.D.; Svendsen, C.N.; Thompson, L.M.; Van Eyk, J.; Maragakis, N.J.; Berry, J.D.; Glass, J.D.; Miller, T.M.; Kolb, S.J.; Baloh, R.H.; Cudkowicz, M.; Baxi, E.; Benatar, M.; Taylor, J.P.; Wu, G.; Rampersaud, E.; Wuu, J.; Rademakers, R.; Züchner, S.; Schule, R.; McCauley, J.; Hussain, S.; Cooley, A.; Wallace, M.; Clayman, C.; Barohn, R.; Statland, J.; Ravits, J.; Swenson, A.; Jackson, C.; Trivedi, J.; Khan, S.; Katz, J.; Jenkins, L.; Burns, T.; Gwathmey, K.; Caress, J.; McMillan, C.; Elman, L.; Pioro, E.; Heckmann, J.; So, Y.; Walk, D.; Maiser, S.; Zhang, J.; Silani, V.; Ticozzi, N.; Gellera, C.; Ratti, A.; Taroni, F.; Lauria, G.; Verde, F.; Fogh, I.; Tiloca, C.; Comi, G.P.; Sorarù, G.; Cereda, C.; D’Alfonso, S.; Corrado, L.; De Marchi, F.; Corti, S.; Ceroni, M.; Mazzini, L.; Siciliano, G.; Filosto, M.; Inghilleri, M.; Peverelli, S.; Colombrita, C.; Poletti, B.; Maderna, L.; Del Bo, R.; Gagliardi, S.; Querin, G.; Bertolin, C.; Pensato, V.; Castellotti, B.; Camu, W.; Mouzat, K.; Lumbroso, S.; Corcia, P.; Meininger, V.; Besson, G.; Lagrange, E.; Clavelou, P.; Guy, N.; Couratier, P.; Vourch, P.; Danel, V.; Bernard, E.; Lemasson, G.; Al Kheifat, A.; Al-Chalabi, A.; Andersen, P.; Basak, A.N.; Blair, I.P.; Chio, A.; Cooper-Knock, J.; Corcia, P.; Couratier, P.; de Carvalho, M.; Dekker, A.; Drory, V.; Redondo, A.G.; Gotkine, M.; Hardiman, O.; Hide, W.; Iacoangeli, A.; Glass, J.; Kenna, K.; Kiernan, M.; Kooyman, M.; Landers, J.; McLaughlin, R.; Middelkoop, B.; Mill, J.; Neto, M.M.; Moisse, M.; Pardina, J.M.; Morrison, K.; Newhouse, S.; Pinto, S.; Pulit, S.; Robberecht, W.; Shatunov, A.; Shaw, P.; Shaw, C.; Silani, V.; Sproviero, W.; Tazelaar, G.; Ticozzi, N.; van Damme, P.; van den Berg, L.; van der Spek, R.; van Eijk, K.; van Es, M.; van Rheenen, W.; van Vugt, J.; Veldink, J.; Weber, M.; Williams, K.L.; Zatz, M.; Bauer, D.C.; Twine, N.A. Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. Neuron 2018 97 6 1268 1283.e6 10.1016/j.neuron.2018.02.027 29566793
130 Ackerley S. Grierson A.J. Banner S. Perkinton M.S. Brownlees J. Byers H.L. Ward M. Thornhill P. Hussain K. Waby J.S. Anderton B.H. Cooper J.D. Dingwall C. Leigh P.N. Shaw C.E. Miller C.C.J. p38α stress-activated protein kinase phosphorylates neurofilaments and is associated with neurofilament pathology in amyotrophic lateral sclerosis. Mol. Cell. Neurosci. 2004 26 2 354 364 10.1016/j.mcn.2004.02.009 15207859
131 Brownlees J. Yates A. Bajaj N.P. Davis D. Anderton B.H. Leigh P.N. Phosphorylation of neurofilament heavy chain side-arms by stress activated protein kinase-1b/Jun N-terminal kinase-3. J. Cell Sci. 2000 113 Pt 3 401 407 10.1242/jcs.113.3.401 10639328
132 Deshpande M. Feiger Z. Shilton A.K. Luo C.C. Silverman E. Rodal A.A. Role of BMP receptor traffic in synaptic growth defects in an ALS model. Mol. Biol. Cell 2016 27 19 2898 2910 10.1091/mbc.E16-07-0519 27535427
133 Aoki Y. Manzano R. Lee Y. Dafinca R. Aoki M. Douglas A.G.L. Varela M.A. Sathyaprakash C. Scaber J. Barbagallo P. Vader P. Mäger I. Ezzat K. Turner M.R. Ito N. Gasco S. Ohbayashi N. El Andaloussi S. Takeda S. Fukuda M. Talbot K. Wood M.J.A. C9orf72 and RAB7L1 regulate vesicle trafficking in amyotrophic lateral sclerosis and frontotemporal dementia. Brain 2017 140 4 887 897 10.1093/brain/awx024 28334866
134 Zhen Y. Stenmark H. Cellular functions of Rab GTPases at a glance. J. Cell Sci. 2015 128 17 jcs.166074 10.1242/jcs.166074 26272922
135 Lai C. Xie C. McCormack S.G. Chiang H.C. Michalak M.K. Lin X. Chandran J. Shim H. Shimoji M. Cookson M.R. Huganir R.L. Rothstein J.D. Price D.L. Wong P.C. Martin L.J. Zhu J.J. Cai H. Amyotrophic lateral sclerosis 2-deficiency leads to neuronal degeneration in amyotrophic lateral sclerosis through altered AMPA receptor trafficking. J. Neurosci. 2006 26 45 11798 11806 10.1523/JNEUROSCI.2084-06.2006 17093100
136 Ritson G.P. Custer S.K. Freibaum B.D. Guinto J.B. Geffel D. Moore J. Tang W. Winton M.J. Neumann M. Trojanowski J.Q. Lee V.M.Y. Forman M.S. Taylor J.P. TDP-43 mediates degeneration in a novel Drosophila model of disease caused by mutations in VCP/p97. J. Neurosci. 2010 30 22 7729 7739 10.1523/JNEUROSCI.5894-09.2010 20519548
137 Gwon Y. Maxwell B.A. Kolaitis R.M. Zhang P. Kim H.J. Taylor J.P. Ubiquitination of G3BP1 mediates stress granule disassembly in a context-specific manner. Science 2021 372 6549 eabf6548 10.1126/science.abf6548 34739333
138 Bertolin C. Querin G. Bozzoni V. Martinelli I. De Bortoli M. Rampazzo A. Gellera C. Pegoraro E. Sorarù G. NewFIG 4 gene mutations causing aggressive ALS. Eur. J. Neurol. 2018 25 3 e41 e42 10.1111/ene.13559 29464931
139 Zhang K. Daigle J.G. Cunningham K.M. Coyne A.N. Ruan K. Grima J.C. Bowen K.E. Wadhwa H. Yang P. Rigo F. Taylor J.P. Gitler A.D. Rothstein J.D. Lloyd T.E. Stress granule assembly disrupts nucleocytoplasmic transport. Cell 2018 173 4 958 971.e17 10.1016/j.cell.2018.03.025 29628143
140 Ederle H. Funk C. Abou-Ajram C. Hutten S. Funk E.B.E. Kehlenbach R.H. Bailer S.M. Dormann D. Nuclear egress of TDP-43 and FUS occurs independently of Exportin-1/CRM1. Sci. Rep. 2018 8 1 7084 10.1038/s41598-018-25007-5 29728564
141 Ciryam P. Antalek M. Cid F. Tartaglia G.G. Dobson C.M. Guettsches A.K. Eggers B. Vorgerd M. Marcus K. Kley R.A. Morimoto R.I. Vendruscolo M. Weihl C.C. A metastable subproteome underlies inclusion formation in muscle proteinopathies. Acta Neuropathol. Commun. 2019 7 1 197 10.1186/s40478-019-0853-9 31796104
142 Yerbury J.J. Farrawell N.E. McAlary L. Proteome homeostasis dysfunction: A unifying principle in ALS pathogenesis. Trends Neurosci. 2020 43 5 274 284 10.1016/j.tins.2020.03.002 32353332
143 Medinas D.B. Valenzuela V. Hetz C. Proteostasis disturbance in amyotrophic lateral sclerosis. Hum. Mol. Genet. 2017 26 R2 R91 R104 10.1093/hmg/ddx274 28977445
144 Bendotti C. Marino M. Cheroni C. Fontana E. Crippa V. Poletti A. De Biasi S. Dysfunction of constitutive and inducible ubiquitin-proteasome system in amyotrophic lateral sclerosis: Implication for protein aggregation and immune response. Prog. Neurobiol. 2012 97 2 101 126 10.1016/j.pneurobio.2011.10.001 22033150
145 Ramesh N. Pandey U.B. Autophagy dysregulation in ALS: When protein aggregates get out of hand. Front. Mol. Neurosci. 2017 10 263 10.3389/fnmol.2017.00263 28878620
146 Prasad A. Bharathi V. Sivalingam V. Girdhar A. Patel B.K. Molecular mechanisms of TDP-43 misfolding and pathology in amyotrophic lateral sclerosis. Front. Mol. Neurosci. 2019 12 25 10.3389/fnmol.2019.00025 30837838
147 Ivanova M.I. Sievers S.A. Guenther E.L. Johnson L.M. Winkler D.D. Galaleldeen A. Aggregation-triggering segments of SOD1 fibril formation support a common pathway for familial and sporadic ALS. Proc. Natl. Acad. Sci. 2014 111 197 10.1073/pnas.1320786110 24344300
148 Deng H.X. Zhai H. Bigio E.H. Yan J. Fecto F. Ajroud K. Mishra M. Ajroud-Driss S. Heller S. Sufit R. Siddique N. Mugnaini E. Siddique T. FUS-immunoreactive inclusions are a common feature in sporadic and non-SOD1 familial amyotrophic lateral sclerosis. Ann. Neurol. 2010 67 6 NA 10.1002/ana.22051 20517935
149 Pokrishevsky E. Grad L.I. Yousefi M. Wang J. Mackenzie I.R. Cashman N.R. Aberrant localization of FUS and TDP43 is associated with misfolding of SOD1 in amyotrophic lateral sclerosis. PLoS One 2012 7 4 e35050 10.1371/journal.pone.0035050 22493728
150 Williams K.L. Warraich S.T. Yang S. Solski J.A. Fernando R. Rouleau G.A. Nicholson G.A. Blair I.P. UBQLN2/ubiquilin 2 mutation and pathology in familial amyotrophic lateral sclerosis. Neurobiol. Aging 2012 33 10 2527.e3 2527.e10 10.1016/j.neurobiolaging.2012.05.008 22717235
151 Schmitz A. Pinheiro M.J. Oertig I. Maharjan N. Saxena S. Emerging perspectives on dipeptide repeat proteins in C9ORF72 ALS/FTD. Front. Cell. Neurosci. 2021 15 637548 10.3389/fncel.2021.637548 33679328
152 Gafson A.R. Barthélemy N.R. Bomont P. Carare R.O. Durham H.D. Julien J.P. Kuhle J. Leppert D. Nixon R.A. Weller R.O. Zetterberg H. Matthews P.M. Neurofilaments: neurobiological foundations for biomarker applications. Brain 2020 143 7 1975 1998 10.1093/brain/awaa098 32408345
153 Kabashi E. Agar J.N. Strong M.J. Durham H.D. Impaired proteasome function in sporadic amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. 2012 13 4 367 371 10.3109/17482968.2012.686511 22632443
154 Cheroni C. Marino M. Tortarolo M. Veglianese P. De Biasi S. Fontana E. Zuccarello L.V. Maynard C.J. Dantuma N.P. Bendotti C. Functional alterations of the ubiquitin-proteasome system in motor neurons of a mouse model of familial amyotrophic lateral sclerosis. Hum. Mol. Genet. 2009 18 1 82 96 10.1093/hmg/ddn319 18826962
155 Kabashi E. Agar J.N. Taylor D.M. Minotti S. Durham H.D. Focal dysfunction of the proteasome: a pathogenic factor in a mouse model of amyotrophic lateral sclerosis. J. Neurochem. 2004 89 6 1325 1335 10.1111/j.1471-4159.2004.02453.x 15189335
156 Kitajima Y. Yoshioka K. Suzuki N. The ubiquitin–proteasome system in regulation of the skeletal muscle homeostasis and atrophy: from basic science to disorders. J. Physiol. Sci. 2020 70 1 40 10.1186/s12576-020-00768-9 32938372
157 Barthelme D. Jauregui R. Sauer R.T. An ALS disease mutation in Cdc48/p97 impairs 20S proteasome binding and proteolytic communication. Protein Sci. 2015 24 9 1521 1527 10.1002/pro.2740 26134898
158 Le N.T.T. Chang L. Kovlyagina I. Georgiou P. Safren N. Braunstein K.E. Kvarta M.D. Van Dyke A.M. LeGates T.A. Philips T. Morrison B.M. Thompson S.M. Puche A.C. Gould T.D. Rothstein J.D. Wong P.C. Monteiro M.J. Motor neuron disease, TDP-43 pathology, and memory deficits in mice expressing ALS–FTD-linked UBQLN2 mutations. Proc. Natl. Acad. Sci. USA 2016 113 47 E7580 E7589 10.1073/pnas.1608432113 27834214
159 Williams K.L. Topp S. Yang S. Smith B. Fifita J.A. Warraich S.T. Zhang K.Y. Farrawell N. Vance C. Hu X. Chesi A. Leblond C.S. Lee A. Rayner S.L. Sundaramoorthy V. Dobson-Stone C. Molloy M.P. van Blitterswijk M. Dickson D.W. Petersen R.C. Graff-Radford N.R. Boeve B.F. Murray M.E. Pottier C. Don E. Winnick C. McCann E.P. Hogan A. Daoud H. Levert A. Dion P.A. Mitsui J. Ishiura H. Takahashi Y. Goto J. Kost J. Gellera C. Gkazi A.S. Miller J. Stockton J. Brooks W.S. Boundy K. Polak M. Muñoz-Blanco J.L. Esteban-Pérez J. Rábano A. Hardiman O. Morrison K.E. Ticozzi N. Silani V. de Belleroche J. Glass J.D. Kwok J.B.J. Guillemin G.J. Chung R.S. Tsuji S. Brown R.H. Jr García-Redondo A. Rademakers R. Landers J.E. Gitler A.D. Rouleau G.A. Cole N.J. Yerbury J.J. Atkin J.D. Shaw C.E. Nicholson G.A. Blair I.P. CCNF mutations in amyotrophic lateral sclerosis and frontotemporal dementia. Nat. Commun. 2016 7 1 11253 10.1038/ncomms11253 27080313
160 Ling S.C. Polymenidou M. Cleveland D.W. Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron 2013 79 3 416 438 10.1016/j.neuron.2013.07.033 23931993
161 Dudman J. Qi X. Stress Granule Dysregulation in Amyotrophic Lateral Sclerosis. Front. Cell. Neurosci. 2020 14 598517 10.3389/fncel.2020.598517 33281563
162 McAlary L. Plotkin S.S. Yerbury J.J. Cashman N.R. Prion-like propagation of protein misfolding and aggregation in amyotrophic lateral sclerosis. Front. Mol. Neurosci. 2019 12 262 10.3389/fnmol.2019.00262 31736708
163 Nolan M. Talbot K. Ansorge O. Pathogenesis of FUS-associated ALS and FTD: insights from rodent models. Acta Neuropathol. Commun. 2016 4 1 99 10.1186/s40478-016-0358-8 27600654
164 Kitamura A. Nakayama Y. Shibasaki A. Taki A. Yuno S. Takeda K. Yahara M. Tanabe N. Kinjo M. Interaction of RNA with a C-terminal fragment of the amyotrophic lateral sclerosis-associated TDP43 reduces cytotoxicity. Sci. Rep. 2016 6 1 19230 10.1038/srep19230 26757674
165 Birsa N. Bentham M.P. Fratta P. Cytoplasmic functions of TDP-43 and FUS and their role in ALS. Semin. Cell Dev. Biol. 2020 99 193 201 10.1016/j.semcdb.2019.05.023 31132467
166 Ratti A. Buratti E. Physiological functions and pathobiology of TDP-43 and FUS/TLS proteins. J. Neurochem. 2016 138 Suppl. 1 95 111 10.1111/jnc.13625 27015757
167 Balendra R. Isaacs A.M. C9orf72-mediated ALS and FTD: multiple pathways to disease. Nat. Rev. Neurol. 2018 14 9 544 558 10.1038/s41582-018-0047-2 30120348
168 Tang X. Toro A. T G, S.; Gao, J.; Chalk, J.; Oskarsson, B.; Zhang, K. Divergence, convergence, and therapeutic implications: A cell biology perspective of C9ORF72-ALS/FTD. Mol. Neurodegener. 2020 15 1 34 10.1186/s13024-020-00383-7 32513219
169 Ayaki T. Ito H. Komure O. Kamada M. Nakamura M. Wate R. Kusaka H. Yamaguchi Y. Li F. Kawakami H. Urushitani M. Takahashi R. Multiple proteinopathies in familial ALS cases with optineurin mutations. J. Neuropathol. Exp. Neurol. 2018 77 2 128 138 10.1093/jnen/nlx109 29272468
170 Münch C. O’Brien J. Bertolotti, A Prion-like propagation of mutant superoxide dismutase-1 misfolding in neuronal cells. Proc. Natl. Acad. Sci. 2011 108 9 3548 3553 10.1073/pnas.1017275108 21321227
171 Geser F. Brandmeir N.J. Kwong L.K. Martinez-Lage M. Elman L. McCluskey L. Xie S.X. Lee V.M.Y. Trojanowski J.Q. Evidence of multisystem disorder in whole-brain map of pathological TDP-43 in amyotrophic lateral sclerosis. Arch. Neurol. 2008 65 5 636 641 10.1001/archneur.65.5.636 18474740
172 Sun Y. Curle A.J. Haider A.M. Balmus G. The role of DNA damage response in amyotrophic lateral sclerosis. Essays Biochem. 2020 64 5 847 861 10.1042/EBC20200002 33078197
173 Hewitt G. Carroll B. Sarallah R. Correia-Melo C. Ogrodnik M. Nelson G. Otten E.G. Manni D. Antrobus R. Morgan B.A. von Zglinicki T. Jurk D. Seluanov A. Gorbunova V. Johansen T. Passos J.F. Korolchuk V.I. SQSTM1/p62 mediates crosstalk between autophagy and the UPS in DNA repair. Autophagy 2016 12 10 1917 1930 10.1080/15548627.2016.1210368 27391408
174 Konopka A. Whelan D.R. Jamali M.S. Perri E. Shahheydari H. Toth R.P. Parakh S. Robinson T. Cheong A. Mehta P. Vidal M. Ragagnin A.M.G. Khizhnyak I. Jagaraj C.J. Galper J. Grima N. Deva A. Shadfar S. Nicholson G.A. Yang S. Cutts S.M. Horejsi Z. Bell T.D.M. Walker A.K. Blair I.P. Atkin J.D. Impaired NHEJ repair in amyotrophic lateral sclerosis is associated with TDP-43 mutations. Mol. Neurodegener. 2020 15 1 51 10.1186/s13024-020-00386-4 32907630
175 Wang H. Guo W. Mitra J. Hegde P.M. Vandoorne T. Eckelmann B.J. Mitra S. Tomkinson A.E. Van Den Bosch L. Hegde M.L. Mutant FUS causes DNA ligation defects to inhibit oxidative damage repair in Amyotrophic Lateral Sclerosis. Nat. Commun. 2018 9 1 3683 10.1038/s41467-018-06111-6 30206235
176 Kawaguchi T. Rollins M.G. Moinpour M. Morera A.A. Ebmeier C.C. Old W.M. Schwartz J.C. Changes to the TDP-43 and FUS Interactomes Induced by DNA Damage. J. Proteome Res. 2020 19 1 360 370 10.1021/acs.jproteome.9b00575 31693373
177 Haeusler A.R. Donnelly C.J. Periz G. Simko E.A.J. Shaw P.G. Kim M.S. Maragakis N.J. Troncoso J.C. Pandey A. Sattler R. Rothstein J.D. Wang J. C9orf72 nucleotide repeat structures initiate molecular cascades of disease. Nature 2014 507 7491 195 200 10.1038/nature13124 24598541
178 Farg M.A. Konopka A. Soo K.Y. Ito D. Atkin J.D. The DNA damage response (DDR) is induced by the C9orf72 repeat expansion in amyotrophic lateral sclerosis. Hum. Mol. Genet. 2017 26 15 2882 2896 10.1093/hmg/ddx170 28481984
179 Nihei Y. Mori K. Werner G. Arzberger T. Zhou Q. Khosravi B. Japtok J. Hermann A. Sommacal A. Weber M. Kamp F. Nuscher B. Edbauer D. Haass C. Poly-glycine–alanine exacerbates C9orf72 repeat expansion-mediated DNA damage via sequestration of phosphorylated ATM and loss of nuclear hnRNPA3. Acta Neuropathol. 2020 139 1 99 118 10.1007/s00401-019-02082-0 31642962
180 Kok J.R. Palminha N.M. Dos Santos Souza C. El-Khamisy S.F. Ferraiuolo L. DNA damage as a mechanism of neurodegeneration in ALS and a contributor to astrocyte toxicity. Cell. Mol. Life Sci. 2021 78 15 5707 5729 10.1007/s00018-021-03872-0 34173837
181 Zhang Y.J. Guo L. Gonzales P.K. Gendron T.F. Wu Y. Jansen-West K. O’Raw A.D. Pickles S.R. Prudencio M. Carlomagno Y. Gachechiladze M.A. Ludwig C. Tian R. Chew J. DeTure M. Lin W.L. Tong J. Daughrity L.M. Yue M. Song Y. Andersen J.W. Castanedes-Casey M. Kurti A. Datta A. Antognetti G. McCampbell A. Rademakers R. Oskarsson B. Dickson D.W. Kampmann M. Ward M.E. Fryer J.D. Link C.D. Shorter J. Petrucelli L. Heterochromatin anomalies and double-stranded RNA accumulation underlie C9orf72 poly(PR) toxicity. Science 2019 363 6428 eaav2606 10.1126/science.aav2606 30765536
182 Tanaka Y. Chen Z.J. STING specifies IRF3 phosphorylation by TBK1 in the cytosolic DNA signaling pathway. Sci. Signal. 2012 5 214 ra20 10.1126/scisignal.2002521 22394562
183 Tadic V. Prell T. Lautenschlaeger J. Grosskreutz J. The ER mitochondria calcium cycle and ER stress response as therapeutic targets in amyotrophic lateral sclerosis. Front. Cell. Neurosci. 2014 8 147 10.3389/fncel.2014.00147 24910594
184 Stoica R. Paillusson S. Gomez-Suaga P. Mitchell J.C. Lau D.H.W. Gray E.H. Sancho R.M. Vizcay-Barrena G. De Vos K.J. Shaw C.E. Hanger D.P. Noble W. Miller C.C.J. ALS/FTD ‐associated FUS activates GSK ‐3β to disrupt the VAPB – PTPIP 51 interaction and ER –mitochondria associations. EMBO Rep. 2016 17 9 1326 1342 10.15252/embr.201541726 27418313
185 Vicencio E. Beltrán S. Labrador L. Manque P. Nassif M. Woehlbier U. Implications of selective autophagy dysfunction for ALS pathology. Cells 2020 9 2 381 10.3390/cells9020381 32046060
186 Sprenkle N.T. Sims S.G. Sánchez C.L. Meares G.P. Endoplasmic reticulum stress and inflammation in the central nervous system. Mol. Neurodegener. 2017 12 1 42 10.1186/s13024-017-0183-y 28545479
187 Lee D.Y. Jeon G.S. Sung J.J. ALS-Linked Mutant SOD1 associates with TIA-1 and alters stress granule dynamics. Neurochem. Res. 2020 45 12 2884 2893 10.1007/s11064-020-03137-5 33025330
188 Matus S. Valenzuela V. Medinas D.B. Hetz C. Er dysfunction and protein folding stress in ALS. Int. J. Cell Biol. 2013 2013 1 12 10.1155/2013/674751 24324498
189 Perri E. Parakh S. Atkin J. Protein Disulphide Isomerases: emerging roles of PDI and ERp57 in the nervous system and as therapeutic targets for ALS. Expert Opin. Ther. Targets 2017 21 1 37 49 10.1080/14728222.2016.1254197 27786579
190 Wang L. Popko B. Roos R.P. The unfolded protein response in familial amyotrophic lateral sclerosis. Hum. Mol. Genet. 2011 20 5 1008 1015 10.1093/hmg/ddq546 21159797
191 Borgese N. Iacomino N. Colombo S.F. Navone F. The Link between VAPB loss of function and amyotrophic lateral sclerosis. Cells 2021 10 8 1865 10.3390/cells10081865 34440634
192 Sundaramoorthy V. Sultana J.M. Atkin J.D. Golgi fragmentation in amyotrophic lateral sclerosis, an overview of possible triggers and consequences. Front. Neurosci. 2015 9 400 10.3389/fnins.2015.00400 26578862
193 van Dis V. Kuijpers M. Haasdijk E.D. Teuling E. Oakes S.A. Hoogenraad C.C. Jaarsma D. Golgi fragmentation precedes neuromuscular denervation and is associated with endosome abnormalities in SOD1-ALS mouse motor neurons. Acta Neuropathol. Commun. 2014 2 1 38 10.1186/2051-5960-2-38 24708899
194 Sasaki S. Iwata M. Mitochondrial alterations in the spinal cord of patients with sporadic amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 2007 66 1 10 16 10.1097/nen.0b013e31802c396b 17204932
195 Singh T. Jiao Y. Ferrando L.M. Yablonska S. Li F. Horoszko E.C. Lacomis D. Friedlander R.M. Carlisle D.L. Neuronal mitochondrial dysfunction in sporadic amyotrophic lateral sclerosis is developmentally regulated. Sci. Rep. 2021 11 1 18916 10.1038/s41598-021-97928-7 34556702
196 Thau N. Knippenberg S. Körner S. Rath K.J. Dengler R. Petri S. Decreased mRNA expression of PGC-1α and PGC-1α-regulated factors in the SOD1G93A ALS mouse model and in human sporadic ALS. J. Neuropathol. Exp. Neurol. 2012 71 12 1064 1074 10.1097/NEN.0b013e318275df4b 23147503
197 Moller A. Bauer C.S. Cohen R.N. Webster C.P. De Vos K.J. Amyotrophic lateral sclerosis-associated mutant SOD1 inhibits anterograde axonal transport of mitochondria by reducing Miro1 levels. Hum. Mol. Genet. 2017 26 23 4668 4679 10.1093/hmg/ddx348 28973175
198 Davis S.A. Itaman S. Khalid-Janney C.M. Sherard J.A. Dowell J.A. Cairns N.J. Gitcho M.A. TDP-43 interacts with mitochondrial proteins critical for mitophagy and mitochondrial dynamics. Neurosci. Lett. 2018 678 8 15 10.1016/j.neulet.2018.04.053 29715546
199 Chen J. Bassot A. Giuliani F. Simmen T. Amyotrophic lateral sclerosis (ALS): Stressed by dysfunctional mitochondria-endoplasmic reticulum contacts (MERCs). Cells 2021 10 7 1789 10.3390/cells10071789 34359958
200 Wang T. Liu H. Itoh K. Oh S. Zhao L. Murata D. Sesaki H. Hartung T. Na C.H. Wang J. C9orf72 regulates energy homeostasis by stabilizing mitochondrial complex I assembly. Cell Metab. 2021 33 3 531 546.e9 10.1016/j.cmet.2021.01.005 33545050
201 Obrador E. Salvador R. López-Blanch R. Jihad-Jebbar A. Vallés S.L. Estrela J.M. Oxidative stress, neuroinflammation and mitochondria in the pathophysiology of amyotrophic lateral sclerosis. Antioxidants 2020 9 9 901 10.3390/antiox9090901 32971909
202 Smith E.F. Shaw P.J. De Vos K.J. The role of mitochondria in amyotrophic lateral sclerosis. Neurosci. Lett. 2019 710 132933 10.1016/j.neulet.2017.06.052 28669745
203 Kazama M. Kato Y. Kakita A. Noguchi N. Urano Y. Masui K. Niida-Kawaguchi M. Yamamoto T. Watabe K. Kitagawa K. Shibata N. Astrocytes release glutamate via cystine/glutamate antiporter upregulated in response to increased oxidative stress related to sporadic amyotrophic lateral sclerosis. Neuropathology 2020 40 6 587 598 10.1111/neup.12716 33305472
204 Pollari E. Goldsteins G. Bart G. Koistinaho J. Giniatullin R. The role of oxidative stress in degeneration of the neuromuscular junction in amyotrophic lateral sclerosis. Front. Cell. Neurosci. 2014 8 131 10.3389/fncel.2014.00131 24860432
205 Tsang C.K. Liu Y. Thomas J. Zhang Y. Zheng X.F.S. Superoxide dismutase 1 acts as a nuclear transcription factor to regulate oxidative stress resistance. Nat. Commun. 2014 5 1 3446 10.1038/ncomms4446 24647101
206 Goh C.W. Lee I.C. Sundaram J.R. George S.E. Yusoff P. Brush M.H. Sze N.S.K. Shenolikar S. Chronic oxidative stress promotes GADD34-mediated phosphorylation of the TAR DNA-binding protein TDP-43, a modification linked to neurodegeneration. J. Biol. Chem. 2018 293 1 163 176 10.1074/jbc.M117.814111 29109149
207 Jagaraj C.J. Parakh S. Atkin J.D. Emerging evidence highlighting the importance of redox dysregulation in the pathogenesis of amyotrophic lateral sclerosis (ALS). Front. Cell. Neurosci. 2021 14 581950 10.3389/fncel.2020.581950 33679322
208 Zala D. Hinckelmann M.V. Yu H. Lyra da Cunha M.M. Liot G. Cordelières F.P. Marco S. Saudou F. Vesicular glycolysis provides on-board energy for fast axonal transport. Cell 2013 152 3 479 491 10.1016/j.cell.2012.12.029 23374344
209 Wang T. Tian X. Kim H.B. Jang Y. Huang Z. Na C.H. Wang J. Intracellular energy controls dynamics of stress-induced ribonucleoprotein granules. Nat. Commun. 2022 13 1 5584 10.1038/s41467-022-33079-1 36151083
210 Rodriguez-Rodriguez P. Fernandez E. Almeida A. Bolaños J.P. Excitotoxic stimulus stabilizes PFKFB3 causing pentose-phosphate pathway to glycolysis switch and neurodegeneration. Cell Death Differ. 2012 19 10 1582 1589 10.1038/cdd.2012.33 22421967
211 Vandoorne T. De Bock K. Van Den Bosch L. Energy metabolism in ALS: an underappreciated opportunity? Acta Neuropathol. 2018 135 4 489 509 10.1007/s00401-018-1835-x 29549424
212 Pennetta G. Welte M.A. Emerging links between lipid droplets and motor neuron diseases. Dev. Cell 2018 45 4 427 432 10.1016/j.devcel.2018.05.002 29787708
213 Cistaro A. Pagani M. Montuschi A. Calvo A. Moglia C. Canosa A. Restagno G. Brunetti M. Traynor B.J. Nobili F. Carrara G. Fania P. Lopiano L. Valentini M.C. Chiò A. The metabolic signature of C9ORF72-related ALS: FDG PET comparison with nonmutated patients. Eur. J. Nucl. Med. Mol. Imaging 2014 41 5 844 852 10.1007/s00259-013-2667-5 24445987
214 Marini C. Morbelli S. Cistaro A. Campi C. Caponnetto C. Bauckneht M. Bellini A. Buschiazzo A. Calamia I. Beltrametti M.C. Margotti S. Fania P. Poggi I. Cabona C. Capitanio S. Piva R. Calvo A. Moglia C. Canosa A. Massone A. Nobili F. Mancardi G. Chiò A. Piana M. Sambuceti G. Interplay between spinal cord and cerebral cortex metabolism in amyotrophic lateral sclerosis. Brain 2018 141 8 2272 2279 10.1093/brain/awy152 30730551
215 Bauckneht M. Lai R. Miceli A. Schenone D. Cossu V. Donegani M.I. Raffa S. Borra A. Marra S. Campi C. Orengo A. Massone A.M. Tagliafico A. Caponnetto C. Cabona C. Cistaro A. Chiò A. Morbelli S. Nobili F. Sambuceti G. Piana M. Marini C. Spinal cord hypermetabolism extends to skeletal muscle in amyotrophic lateral sclerosis: a computational approach to [18F]-fluorodeoxyglucose PET/CT images. EJNMMI Res. 2020 10 1 23 10.1186/s13550-020-0607-5 32201914
216 Miyazaki K. Masamoto K. Morimoto N. Kurata T. Mimoto T. Obata T. Kanno I. Abe K. Early and progressive impairment of spinal blood flow-glucose metabolism coupling in motor neuron degeneration of ALS model mice. J. Cereb. Blood Flow Metab. 2012 32 3 456 467 10.1038/jcbfm.2011.155 22068226
217 Dodge J.C. Treleaven C.M. Fidler J.A. Tamsett T.J. Bao C. Searles M. Taksir T.V. Misra K. Sidman R.L. Cheng S.H. Shihabuddin L.S. Metabolic signatures of amyotrophic lateral sclerosis reveal insights into disease pathogenesis. Proc. Natl. Acad. Sci. USA 2013 110 26 10812 10817 10.1073/pnas.1308421110 23754387
218 Tefera T.W. Steyn F.J. Ngo S.T. Borges K. CNS glucose metabolism in Amyotrophic Lateral Sclerosis: a therapeutic target? Cell Biosci. 2021 11 1 14 10.1186/s13578-020-00511-2 33431046
219 Steyn F.J. Li R. Kirk S.E. Tefera T.W. Xie T.Y. Tracey T.J. Kelk D. Wimberger E. Garton F.C. Roberts L. Chapman S.E. Coombes J.S. Leevy W.M. Ferri A. Valle C. René F. Loeffler J.P. McCombe P.A. Henderson R.D. Ngo S.T. Altered skeletal muscle glucose-fatty acid flux in amyotrophic lateral sclerosis. Brain Commun. 2020 2 2 fcaa154 10.1093/braincomms/fcaa154 33241210
220 Tefera T.W. Borges K. Neuronal glucose metabolism is impaired while astrocytic TCA cycling is unaffected at symptomatic stages in the hSOD1 G93A mouse model of amyotrophic lateral sclerosis. J. Cereb. Blood Flow Metab. 2019 39 9 1710 1724 10.1177/0271678X18764775 29553298
221 Lee H. Lee J.J. Park N.Y. Dubey S.K. Kim T. Ruan K. Lim S.B. Park S.H. Ha S. Kovlyagina I. Kim K. Kim S. Oh Y. Kim H. Kang S.U. Song M.R. Lloyd T.E. Maragakis N.J. Hong Y.B. Eoh H. Lee G. Multi-omic analysis of selectively vulnerable motor neuron subtypes implicates altered lipid metabolism in ALS. Nat. Neurosci. 2021 24 12 1673 1685 10.1038/s41593-021-00944-z 34782793
222 Palamiuc L. Schlagowski A. Ngo S.T. Vernay A. Dirrig-Grosch S. Henriques A. Boutillier A.L. Zoll J. Echaniz-Laguna A. Loeffler J.P. René F. A metabolic switch toward lipid use in glycolytic muscle is an early pathologic event in a mouse model of amyotrophic lateral sclerosis. EMBO Mol. Med. 2015 7 5 526 546 10.15252/emmm.201404433 25820275
223 Yudkoff M. Daikhin Y. Horyn O. Nissim I. Nissim I. Ketosis and brain handling of glutamate, glutamine, and GABA. Epilepsia 2008 49 Suppl. 8 73 75 10.1111/j.1528-1167.2008.01841.x 19049594
224 Scaricamazza S. Salvatori I. Giacovazzo G. Loeffler J.P. Renè F. Rosina M. Quessada C. Proietti D. Heil C. Rossi S. Battistini S. Giannini F. Volpi N. Steyn F.J. Ngo S.T. Ferraro E. Madaro L. Coccurello R. Valle C. Ferri A. Skeletal-muscle metabolic reprogramming in ALS-SOD1G93A mice predates disease onset and is a promising therapeutic target. iScience 2020 23 5 101087 10.1016/j.isci.2020.101087 32371370
225 Szelechowski M. Amoedo N. Obre E. Léger C. Allard L. Bonneu M. Claverol S. Lacombe D. Oliet S. Chevallier S. Le Masson G. Rossignol R. Metabolic reprogramming in amyotrophic lateral sclerosis. Sci. Rep. 2018 8 1 3953 10.1038/s41598-018-22318-5 29500423
226 Dodge J.C. Jensen E.H. Yu J. Sardi S.P. Bialas A.R. Taksir T.V. Bangari D.S. Shihabuddin L.S. Neutral lipid cacostasis contributes to disease pathogenesis in amyotrophic lateral sclerosis. J. Neurosci. 2020 40 47 9137 9147 10.1523/JNEUROSCI.1388-20.2020 33051352
227 Henriques A. Huebecker M. Blasco H. Keime C. Andres C.R. Corcia P. Priestman D.A. Platt F.M. Spedding M. Loeffler J.P. Inhibition of β-Glucocerebrosidase activity preserves motor unit integrity in a mouse model of amyotrophic lateral sclerosis. Sci. Rep. 2017 7 1 5235 10.1038/s41598-017-05313-0 28701774
228 Sipione S. Monyror J. Galleguillos D. Steinberg N. Kadam V. Gangliosides in the brain: Physiology, pathophysiology and therapeutic applications. Front. Neurosci. 2020 14 572965 10.3389/fnins.2020.572965 33117120
229 Tracey T.J. Steyn F.J. Wolvetang E.J. Ngo S.T. Neuronal lipid metabolism: multiple pathways driving functional outcomes in health and disease. Front. Mol. Neurosci. 2018 11 10 10.3389/fnmol.2018.00010 29410613
230 Schmitt F. Hussain G. Dupuis L. Loeffler J.P. Henriques A. A plural role for lipids in motor neuron diseases: Energy, signaling and structure. Front. Cell. Neurosci. 2014 8 25 10.3389/fncel.2014.00025 24600344
231 Mouzat K. Molinari N. Kantar J. Polge A. Corcia P. Couratier P. Clavelou P. Juntas-Morales R. Pageot N. Lobaccaro J.M.A. Raoul C. Lumbroso S. Camu W. Liver X receptor genes variants modulate ALS phenotype. Mol. Neurobiol. 2018 55 3 1959 1965 10.1007/s12035-017-0453-2 28244008
232 Wills A.M. Hubbard J. Macklin E.A. Glass J. Tandan R. Simpson E.P. Brooks B. Gelinas D. Mitsumoto H. Mozaffar T. Hanes G.P. Ladha S.S. Heiman-Patterson T. Katz J. Lou J.S. Mahoney K. Grasso D. Lawson R. Yu H. Cudkowicz M. Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet 2014 383 9934 2065 2072 10.1016/S0140-6736(14)60222-1 24582471
233 Fang F. Ingre C. Roos P. Kamel F. Piehl F. Risk factors for amyotrophic lateral sclerosis. Clin. Epidemiol. 2015 7 181 193 10.2147/CLEP.S37505 25709501
234 Goutman S.A. Feldman E.L. Voicing the Need for Amyotrophic Lateral Sclerosis Environmental Research. JAMA Neurol. 2020 77 5 543 544 10.1001/jamaneurol.2020.0051 32119032
235 Allis C.D. Jenuwein T. The molecular hallmarks of epigenetic control. Nat. Rev. Genet. 2016 17 8 487 500 10.1038/nrg.2016.59 27346641
236 Worpenberg L. Paolantoni C. Roignant J-Y. Functional interplay within the epitranscriptome: Reality or fiction? BioEssays 2021 e2100174 10.1002/bies.202100174 34873719
237 Appleby-Mallinder C. Schaber E. Kirby J. Shaw P.J. Cooper-Knock J. Heath P.R. Highley J.R. TDP43 proteinopathy is associated with aberrant DNA methylation in human amyotrophic lateral sclerosis. Neuropathol. Appl. Neurobiol. 2021 47 1 61 72 10.1111/nan.12625 32365404
238 Ozyurt T. Gautam M. Differential epigenetic signature of corticospinal motor neurons in ALS. Brain Sci. 2021 11 6 754 10.3390/brainsci11060754 34200232
239 Xi Z. Zhang M. Bruni A.C. Maletta R.G. Colao R. Fratta P. Polke J.M. Sweeney M.G. Mudanohwo E. Nacmias B. Sorbi S. Tartaglia M.C. Rainero I. Rubino E. Pinessi L. Galimberti D. Surace E.I. McGoldrick P. McKeever P. Moreno D. Sato C. Liang Y. Keith J. Zinman L. Robertson J. Rogaeva E. The C9orf72 repeat expansion itself is methylated in ALS and FTLD patients. Acta Neuropathol. 2015 129 5 715 727 10.1007/s00401-015-1401-8 25716178
240 Wong M. Gertz B. Chestnut B.A. Martin L.J. Mitochondrial DNMT3A and DNA methylation in skeletal muscle and CNS of transgenic mouse models of ALS. Front. Cell. Neurosci. 2013 7 279 10.3389/fncel.2013.00279 24399935
241 Simpson C.L. Lemmens R. Miskiewicz K. Broom W.J. Hansen V.K. van Vught P.W.J. Landers J.E. Sapp P. Van Den Bosch L. Knight J. Neale B.M. Turner M.R. Veldink J.H. Ophoff R.A. Tripathi V.B. Beleza A. Shah M.N. Proitsi P. Van Hoecke A. Carmeliet P. Horvitz H.R. Leigh P.N. Shaw C.E. van den Berg L.H. Sham P.C. Powell J.F. Verstreken P. Brown R.H. Jr Robberecht W. Al-Chalabi A. Variants of the elongator protein 3 (ELP3) gene are associated with motor neuron degeneration. Hum. Mol. Genet. 2009 18 3 472 481 10.1093/hmg/ddn375 18996918
242 Taes I. Timmers M. Hersmus N. Bento-Abreu A. Van Den Bosch L. Van Damme P. Auwerx J. Robberecht W. Hdac6 deletion delays disease progression in the SOD1G93A mouse model of ALS. Hum. Mol. Genet. 2013 22 9 1783 1790 10.1093/hmg/ddt028 23364049
243 Chen S. Zhang X.J. Li L.X. Wang Y. Zhong R.J. Le W. Histone deacetylase 6 delays motor neuron degeneration by ameliorating the autophagic flux defect in a transgenic mouse model of amyotrophic lateral sclerosis. Neurosci. Bull. 2015 31 4 459 468 10.1007/s12264-015-1539-3 26164555
244 Pigna E. Simonazzi E. Sanna K. Bernadzki K.M. Proszynski T. Heil C. Palacios D. Adamo S. Moresi V. Histone deacetylase 4 protects from denervation and skeletal muscle atrophy in a murine model of amyotrophic lateral sclerosis. EBioMedicine 2019 40 717 732 10.1016/j.ebiom.2019.01.038 30713114
245 Tibshirani M. Tradewell M.L. Mattina K.R. Minotti S. Yang W. Zhou H. Strong M.J. Hayward L.J. Durham H.D. Cytoplasmic sequestration of FUS/TLS associated with ALS alters histone marks through loss of nuclear protein arginine methyltransferase 1. Hum. Mol. Genet. 2015 24 3 773 786 10.1093/hmg/ddu494 25274782
246 Masala A. Sanna S. Esposito S. Rassu M. Galioto M. Zinellu A. Carru C. Carrì M.T. Iaccarino C. Crosio C. Epigenetic changes associated with the expression of amyotrophic lateral sclerosis (ALS) causing genes. Neuroscience 2018 390 1 11 10.1016/j.neuroscience.2018.08.009 30134203
247 Vijayakumar U.G. Milla V. Cynthia Stafford M.Y. Bjourson A.J. Duddy W. Duguez S.M.R. A systematic review of suggested molecular strata, biomarkers and their tissue sources in ALS. Front. Neurol. 2019 10 400 10.3389/fneur.2019.00400 31139131
248 Foggin S. Mesquita-Ribeiro R. Dajas-Bailador F. Layfield R. Biological significance of microRNA biomarkers in ALS-innocent bystanders or disease culprits? Front. Neurol. 2019 10 578 10.3389/fneur.2019.00578 31244752
249 Ravnik-Glavač M. Glavač D. Circulating RNAs as potential Biomarkers in amyotrophic lateral sclerosis. Int. J. Mol. Sci. 2020 21 5 1714 10.3390/ijms21051714 32138249
250 Angelova M.T. Dimitrova D.G. Dinges N. Lence T. Worpenberg L. Carré C. Roignant J.Y. The emerging field of epitranscriptomics in neurodevelopmental and neuronal disorders. Front. Bioeng. Biotechnol. 2018 6 46 10.3389/fbioe.2018.00046 29707539
251 Hosaka T. Tsuji H. Tamaoka A. Biomolecular modifications linked to oxidative stress in amyotrophic lateral sclerosis: determining promising biomarkers related to oxidative stress. Processes (Basel) 2021 9 9 1667 10.3390/pr9091667
252 Hideyama T. Yamashita T. Aizawa H. Tsuji S. Kakita A. Takahashi H. Kwak S. Profound downregulation of the RNA editing enzyme ADAR2 in ALS spinal motor neurons. Neurobiol. Dis. 2012 45 3 1121 1128 10.1016/j.nbd.2011.12.033 22226999
253 Sasaki S. Yamashita T. Shin K. Autophagy in spinal motor neurons of conditional ADAR2-knockout mice: An implication for a role of calcium in increased autophagy flux in ALS. Neurosci. Lett. 2015 598 79 84 10.1016/j.neulet.2015.05.025 25980994
254 Moore S. Alsop E. Lorenzini I. Starr A. Rabichow B.E. Mendez E. Levy J.L. Burciu C. Reiman R. Chew J. Belzil V.V. W. Dickson D. Robertson, J.; Staats, K.A.; Ichida, J.K.; Petrucelli, L.; Van Keuren-Jensen, K.; Sattler, R. ADAR2 mislocalization and widespread RNA editing aberrations in C9orf72-mediated ALS/FTD. Acta Neuropathol. 2019 138 1 49 65 10.1007/s00401-019-01999-w 30945056
255 Quoibion A. m6A RNA Methylation and TARDBP, a Gene Implicated in Amyotrophic Lateral Sclerosis. McGill University: Montréal 2017 Thesis.
256 Kim H.J. Kim N.C. Wang Y.D. Scarborough E.A. Moore J. Diaz Z. MacLea K.S. Freibaum B. Li S. Molliex A. Kanagaraj A.P. Carter R. Boylan K.B. Wojtas A.M. Rademakers R. Pinkus J.L. Greenberg S.A. Trojanowski J.Q. Traynor B.J. Smith B.N. Topp S. Gkazi A.S. Miller J. Shaw C.E. Kottlors M. Kirschner J. Pestronk A. Li Y.R. Ford A.F. Gitler A.D. Benatar M. King O.D. Kimonis V.E. Ross E.D. Weihl C.C. Shorter J. Taylor J.P. Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Nature 2013 495 7442 467 473 10.1038/nature11922 23455423
257 Mitropoulos K. Merkouri P.E. Xiromerisiou G. Balasopoulou A. Charalampidou K. Galani V. Zafeiri K.V. Dardiotis E. Ralli S. Deretzi G. John A. Kydonopoulou K. Papadopoulou E. di Pardo A. Akcimen F. Loizedda A. Dobričić V. Novaković I. Kostić V.S. Mizzi C. Peters B.A. Basak N. Orrù S. Kiskinis E. Cooper D.N. Gerou S. Drmanac R. Bartsakoulia M. Tsermpini E.E. Hadjigeorgiou G.M. Ali B.R. Katsila T. Patrinos G.P. Genomic variants in the FTO gene are associated with sporadic amyotrophic lateral sclerosis in Greek patients. Hum. Genomics 2017 11 1 30 10.1186/s40246-017-0126-2 29216901
258 Blanco S. Dietmann S. Flores J.V. Hussain S. Kutter C. Humphreys P. Lukk M. Lombard P. Treps L. Popis M. Kellner S. Hölter S.M. Garrett L. Wurst W. Becker L. Klopstock T. Fuchs H. Gailus-Durner V. Hrabĕ de Angelis M. Káradóttir R.T. Helm M. Ule J. Gleeson J.G. Odom D.T. Frye M. Aberrant methylation of t RNA s links cellular stress to neuro‐developmental disorders. EMBO J. 2014 33 18 2020 2039 10.15252/embj.201489282 25063673
259 Hartung T. Rhein M. Kalmbach N. Thau-Habermann N. Naujock M. Müschen L. Frieling H. Sterneckert J. Hermann A. Wegner F. Petri S. Methylation and expression of mutant FUS in motor neurons differentiated from induced pluripotent stem cells from ALS patients. Front. Cell Dev. Biol. 2021 9 774751 10.3389/fcell.2021.774751 34869374
260 Hogg M.C. Rayner M. Susdalzew S. Monsefi N. Crivello M. Woods I. Resler A. Blackbourn L. Fabbrizio P. Trolese M.C. Nardo G. Bendotti C. van den Berg L.H. van Es M.A. Prehn J.H.M. 5′ValCAC tRNA fragment generated as part of a protective angiogenin response provides prognostic value in amyotrophic lateral sclerosis. Brain Commun. 2020 2 2 fcaa138 10.1093/braincomms/fcaa138 33543130
261 Taylor R. Hamid F. Fielding T. Gordon P.M. Maloney M. Makeyev E.V. Houart C. Prematurely terminated intron-retaining mRNAs invade axons in SFPQ null-driven neurodegeneration and are a hallmark of ALS. Nat. Commun. 2022 13 1 6994 10.1038/s41467-022-34331-4 36414621
262 Mead R.J. Shan N. Reiser H.J. Marshall F. Shaw P.J. Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translation. Nat. Rev. Drug Discov. 2023 22 3 185 212 10.1038/s41573-022-00612-2 36543887
263 Corcia P. Beltran S. Bakkouche S.E. Couratier P. Therapeutic news in ALS. Rev. Neurol. 2021 177 5 544 549 10.1016/j.neurol.2020.12.003 33781562
264 Ketabforoush A.H.M.E. Chegini R. Barati S. Tahmasebi F. Moghisseh B. Joghataei M.T. Faghihi F. Azedi F. Masitinib: The promising actor in the next season of the amyotrophic lateral sclerosis treatment series. Biomed. Pharmacother. 2023 160 114378 10.1016/j.biopha.2023.114378 36774721
265 Eisen A. Kim S. Pant B. Amyotrophic lateral sclerosis (ALS): A phylogenetic disease of the corticomotoneuron? Muscle Nerve 1992 15 2 219 224 10.1002/mus.880150215 1549143
266 Marques C. Burg T. Scekic-Zahirovic J. Fischer M. Rouaux C. Upper and lower motor neuron degenerations are somatotopically related and temporally ordered in the Sod1 mouse model of amyotrophic lateral sclerosis. Brain Sci. 2021 11 3 369 10.3390/brainsci11030369 33805792
267 Lu S. Hu J. Arogundade O.A. Goginashvili A. Vazquez-Sanchez S. Diedrich J.K. Gu J. Blum J. Oung S. Ye Q. Yu H. Ravits J. Liu C. Yates J.R. III Cleveland D.W. Heat-shock chaperone HSPB1 regulates cytoplasmic TDP-43 phase separation and liquid-to-gel transition. Nat. Cell Biol. 2022 24 9 1378 1393 10.1038/s41556-022-00988-8 36075972
268 Pradhan J. Noakes P.G. Bellingham M.C. The role of altered BDNF/TrkB signaling in amyotrophic lateral sclerosis. Front. Cell. Neurosci. 2019 13 368 10.3389/fncel.2019.00368 31456666
269 Paganoni S. Berry J.D. Quintana M. Macklin E. Saville B.R. Detry M.A. Chase M. Sherman A.V. Yu H. Drake K. Andrews J. Shefner J. Chibnik L.B. Vestrucci M. Cudkowicz M.E. Adaptive platform trials to transform amyotrophic lateral sclerosis therapy development. Ann. Neurol. 2022 91 2 165 175 10.1002/ana.26285 34935174
270 Jacquez G.M. Sabel C.E. Shi C. Genetic GIScience: toward a place-based synthesis of the genome, exposome, and behavome. Ann. Assoc. Am. Geogr. 2015 105 3 454 472 10.1080/00045608.2015.1018777 26339073
271 Fidler J.A. Treleaven C.M. Frakes A. Tamsett T.J. McCrate M. Cheng S.H. Shihabuddin L.S. Kaspar B.K. Dodge J.C. Disease progression in a mouse model of amyotrophic lateral sclerosis: the influence of chronic stress and corticosterone. FASEB J. 2011 25 12 4369 4377 10.1096/fj.11-190819 21876068
272 Calabrese V. Mancuso C. Calvani M. Rizzarelli E. Butterfield D.A. Giuffrida Stella A.M. Nitric oxide in the central nervous system: neuroprotection versus neurotoxicity. Nat. Rev. Neurosci. 2007 8 10 766 775 10.1038/nrn2214 17882254
273 Calabrese V. Cornelius C. Dinkova-Kostova A.T. Calabrese E.J. Mattson M.P. Cellular stress responses, the hormesis paradigm, and vitagenes: novel targets for therapeutic intervention in neurodegenerative disorders. Antioxid. Redox Signal. 2010 13 11 1763 1811 10.1089/ars.2009.3074 20446769
274 Calabrese V. Cornelius C. Dinkova-Kostova A.T. Calabrese E.J. Vitagenes, cellular stress response, and acetylcarnitine: Relevance to hormesis. Biofactors 2009 35 2 146 160 10.1002/biof.22 19449442
275 Anzilotti S. Brancaccio P. Simeone G. Valsecchi V. Vinciguerra A. Secondo A. Petrozziello T. Guida N. Sirabella R. Cuomo O. Cepparulo P. Herchuelz A. Amoroso S. Di Renzo G. Annunziato L. Pignataro G. Preconditioning, induced by sub-toxic dose of the neurotoxin L-BMAA, delays ALS progression in mice and prevents Na+/Ca2+ exchanger 3 downregulation. Cell Death Dis. 2018 9 2 206 10.1038/s41419-017-0227-9 29434186
276 Siracusa R. Scuto M. Fusco R. Trovato A. Ontario M.L. Crea R. Di Paola R. Cuzzocrea S. Calabrese V. Anti-inflammatory and anti-oxidant activity of Hidrox® in rotenone-induced Parkinson’s disease in mice. Antioxidants 2020 9 9 824 10.3390/antiox9090824 32899274
277 Kim D. Nguyen M.D. Dobbin M.M. Fischer A. Sananbenesi F. Rodgers J.T. Delalle I. Baur J.A. Sui G. Armour S.M. Puigserver P. Sinclair D.A. Tsai L.H. SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer’s disease and amyotrophic lateral sclerosis. EMBO J. 2007 26 13 3169 3179 10.1038/sj.emboj.7601758 17581637
278 Calabrese E.J. Calabrese V. Giordano J. Brain health promotion: Tactics within a strategic approach based upon valid, yet evolving scientific evidence. Mech. Ageing Dev. 2022 201 111605 10.1016/j.mad.2021.111605 34798081
279 Bauer P.O. Methylation of C9orf72 expansion reduces RNA foci formation and dipeptide-repeat proteins expression in cells. Neurosci. Lett. 2016 612 204 209 10.1016/j.neulet.2015.12.018 26690922
280 Lam F. Chu J. Choi J.S. Cao C. Hitchens T.K. Silverman S.K. Epigenetic MRI: noninvasive imaging of DNA methylation in the brain. BioRxiv 2021 2021.08.20.457113 10.1101/2021.08.20.457113
281 Choi S.Y. Lee J.H. Chung A.Y. Jo Y. Shin J. Park H.C. Kim H. Lopez-Gonzalez R. Ryu J.R. Sun W. Prevention of mitochondrial impairment by inhibition of protein phosphatase 1 activity in amyotrophic lateral sclerosis. Cell Death Dis. 2020 11 10 888 10.1038/s41419-020-03102-8 33087694
282 Paganoni S. Hendrix S. Dickson S.P. Knowlton N. Berry J.D. Elliott M.A. Effect of sodium phenylbutyrate/taurursodiol on tracheostomy/ventilation-free survival and hospitalisation in amyotrophic lateral sclerosis: Long-term results from the Centaur trial. J Neurol. Neurosurg. Amp. Psychiatry 2022 93 871 10.1136/jnnp-2022-329024
283 Klingl Y.E. Pakravan D. Van Den B.L. Opportunities for histone deacetylase inhibition in amyotrophic lateral sclerosis. Br. J. Pharmacol. 2020 178 6 1353 1372 10.1111/bph.15217 32726472
284 Xia Z. Tang M. Ma J. Zhang H. Gimple R.C. Prager B.C. Tang H. Sun C. Liu F. Lin P. Mei Y. Du R. Rich J.N. Xie Q. Epitranscriptomic editing of the RNA N6-methyladenosine modification by dCasRx conjugated methyltransferase and demethylase. Nucleic Acids Res. 2021 49 13 7361 7374 10.1093/nar/gkab517 34181729
285 Batra R. Nelles D.A. Pirie E. Blue S.M. Marina R.J. Wang H. Chaim I.A. Thomas J.D. Zhang N. Nguyen V. Aigner S. Markmiller S. Xia G. Corbett K.D. Swanson M.S. Yeo G.W. Elimination of toxic microsatellite repeat expansion RNA by RNA-targeting Cas9. Cell 2017 170 5 899 912.e10 10.1016/j.cell.2017.07.010 28803727
286 Keogh M.J. Wei W. Aryaman J. Wilson I. Talbot K. Turner M.R. McKenzie C.A. Troakes C. Attems J. Smith C. Al Sarraj S. Morris C.M. Ansorge O. Pickering-Brown S. Jones N. Ironside J.W. Chinnery P.F. Oligogenic genetic variation of neurodegenerative disease genes in 980 postmortem human brains. J. Neurol. Neurosurg. Psychiatry 2018 89 8 813 816 10.1136/jnnp-2017-317234 29332010
287 Chiò A. Mazzini L. D’Alfonso S. Corrado L. Canosa A. Moglia C. Manera U. Bersano E. Brunetti M. Barberis M. Veldink J.H. van den Berg L.H. Pearce N. Sproviero W. McLaughlin R. Vajda A. Hardiman O. Rooney J. Mora G. Calvo A. Al-Chalabi A. The multistep hypothesis of ALS revisited. Neurology 2018 91 7 e635 e642 10.1212/WNL.0000000000005996 30045958
